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ABSTRACT 
 
THE EFFECT OF SEQUENTIAL EXPOSURE TO ANTIGENICALLY DRIFTED STRAINS OF 
INFLUENZA ON ANTIBODY SPECIFICITY AND ANTIBODY MEDIATED PROTECTION 
Susanne L Linderman 
Scott E Hensley 
Antibodies (Abs) elicited by influenza viruses often bind with higher affinities to past influenza 
strains than to the current strain.  This has been associated with the hypothesis of “original 
antigenic sin” which postulates that B cell clones elicited by prior exposure are recalled at the 
expense of generating a strain-specific response to the current strain.  It is clear that prior 
exposures to influenza viruses focus the response on conserved epitopes of influenza’s 
hemagglutinin (HA) glycoprotein. Here, pre-exposure to influenza is shown to affect Ab fine 
specificity and Ab mediated protection in mice, ferrets, and humans.  Sequential vaccination of 
mice with antigenically drifted strains of influenza virus elicited a large proportion of cross-reactive 
Abs, but also recalled Abs that have a higher affinity for the priming strain while binding to the 
same region of HA with different fine specificities.  These fine specificities were modified by 
somatic hypermutation, which affected the degree of cross-reactivity.  Surprisingly, Abs that 
bound with relatively low affinities to an antigenically drifted strain effectively neutralized the 
drifted strain following passive transfer.  This indicates that Abs expressed by recalled B cell 
clones share some level of cross-reactivity between antigenically drifted priming and recall 
strains. This was also observed by measuring the reactivity of sera to HA of antigenically drifted 
influenza strains.  Similarly, ferrets and humans sequentially exposed to influenza viruses had Ab 
repertoires that were focused on epitopes conserved between recent strains and earlier strains 
that circulated during their childhood.  As influenza viruses continually mutate, humans had Ab 
repertoires that were focused on different regions of the HA, potentially due to unique pre-
exposure histories.  A recently acquired HA mutation abrogated binding of Abs predominantly 
found in middle-aged adults that were unusually susceptible to influenza infection during the 
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2013-2014 influenza season.  These findings highlight that while weakly cross-reactive Abs can 
protect against antigenically drifted strains, shifting the Ab repertoire to partially conserved sites 
can focus the response on regions of the virus that undergo continual antigenic drift.  Recall of 
cross-reactive Abs can thus result in protection or susceptibility to influenza, depending upon the 
exposure history and Ab fine specificities. 
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CHAPTER 1:  INTRODUCTION 
 
Influenza causes an annual disease burden throughout the world, and has for 
centuries.  Influenza-like epidemics have been recorded throughout history, though 
before the isolation of the causative influenza virus, these epidemics were often 
considered to be new diseases, particularly since they frequently overcame previously 
acquired immunity (Francis, 1953; Smith et al., 1933).  In 1562, Sir Thomas Randolph, 
the Ambassador of Queen Elizabeth I to the Court of Mary, Queen of Scots, recorded in 
a letter, “May it please your Honour immediately upon the Queen’s arrival here, she fell 
acquainted with a new disease that is common in this town, called here the New 
Acquaintance, which passed also through her whole Court, neither sparing lord, lady, 
nor demoiselle, not so much as either French or English” (Strickland, 1903). Not all 
pandemics were equal in their epidemiological distribution though.  For instance, English 
reports of the pandemic of 1782 describe that children and the elderly were less affected 
than middle-aged adults (Francis, 1953).   
We now know that influenza viruses frequently cause epidemics because they 
can rapidly change, either by acquiring mutations or by gene recombination.  In addition, 
we know that serum components known as antibodies (Abs) can protect against 
infection, and that the Ab repertoire is diverse and can continue to evolve over time 
(Briney and Crowe, 2013; Von Stabsarzt and Kutasati, 1890). In chapter two, we will 
describe how sequential exposure to variant influenza strains affects the fine specificity 
of influenza-specific Abs and influences protection against infection in mice.  In chapter 
three we will address how pre-exposure history in humans affects the Ab repertoire and 
may influence susceptibility to disease.  But first in chapter one, we will review 
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immunological and virological studies that shape our current knowledge of the B cell 
response to influenza and outline the larger immunologic context of the ensuing 
experimental questions. 
A diverse repertoire of B cells express antibodies 
B cells are lymphocytes that have successfully rearranged their immunoglobulin 
locus to express functional Abs.  Functional Abs consist of four chains: two heavy chains 
and two light chains (or up to 6 multiples of that) (Cattaneo and Neuberger, 1987; 
Edelman, 1973).  Each heavy and light chain of an antibody molecule has a variable 
region and a constant region.  The variable regions are formed by gene recombination. 
In the heavy chain locus, the heavy chain variable region is created by sequential 
rearrangements involving one V (variable), one D (diversity), and one J (joining) gene 
segment.  The light chain variable regions consist of one V gene rearranged to one J 
gene (Early et al., 1980; Hozumi and Tonegawa, 1976).  In addition to the combinatorial 
diversity that is generated by the random rearrangement of these gene segments and by 
the independent pairing of the heavy and light chains, additional variability is introduced 
at the junctional sequences between the different gene regions as nucleotides can be 
added or lost during RAG (recombination-activating gene) mediated recombination (Alt 
and Baltimore, 1982).  This junctional diversification can include the addition of 
palindromic sequences by RAG (P-addition), the addition of random nucleotides by the 
enzyme terminal deoxynucleotidyl transferase (N-addition), and the exonucleolytic 
nibbling by non-homologous end joining machinery (deletions).  Due to the high degree 
of junctional diversity, the resulting rearrangement may result in a non-functional 
rearrangement (due to shifts in the reading frame or the generation of termination 
codons).  Should recombination lead to a nonproductive rearrangement, the second 
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immunoglobulin allele can be rearranged. Usually only one allele is expressed (allelic 
exclusion), so that B cells usually express only one kind of antibody molecule 
(Vettermann and Schlissel, 2010).  B cells harboring Abs that exhibit binding to self-
antigens in the bone marrow are eliminated or disabled in a process known as negative 
selection (Hartley et al., 1991; Vettermann and Schlissel, 2010).  In some cases, self-
reactive B cells may be saved by modifying the specificity of the antibody through 
additional gene rearrangement, a process known as receptor editing (Luning Prak et al., 
2011).   
In addition to the variable region genes, each Ab heavy chain also has a constant 
region gene that determines the isotype (eg. IgM, IgD, IgG, IgA, or IgE).  The isotype 
produced by a particular B cell can change over time through class switch recombination 
and imparts important functional properties to Ab activity (Stavnezer et al., 2008).  For 
instance, IgA can be transported to mucosal surfaces such as the gut, and can be 
transferred into secretions such as saliva and milk while IgG can be transported across 
the placenta and provide early protection to infants (Garty et al., 1994; Palmeira et al., 
2012; Van de Perre, 2003).  Ab heavy chain isotypes also differ in their ability to bind to 
different Fc receptors which, in turn, can either enhance or suppress the immune 
response.  This can be further modified by differential glycosylation of the Fc region, thus 
altering the type of receptor to which the Fc region can bind (Pincetic et al., 2014).  In 
addition, changes in isotype have been shown to affect both avidity and affinity to 
antigen (Cooper et al., 1993; Tudor et al., 2012).  Abs can be secreted as soluble 
proteins or expressed on the cell membrane as the B cell receptor (BCR) when 
alternatively spliced to include a transmembrane domain.  
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The BCR has the ability to bind to particular structural epitopes, and can 
transduce a signal across the cell membrane upon binding through its association with 
the Igα and Igβ coreceptors (Sanchez et al., 1993).  This initial signal leads to significant 
changes in the cell that affect antigen uptake, processing, presentation on major 
histocompatibility complex II (MHCII), costimulatory molecule expression, and homing 
which make B cells effective antigen presenting cells.  Naïve B cells circulate through 
the blood and lymph and home to secondary lymphoid organs including lymph nodes 
and the spleen (Butcher and Picker, 1996).  Upon encountering antigen, B cells 
upregulate the chemokine receptor CCR7 which binds to the chemokines CCL19 and 
CCL21 which are expressed at the interface of the B and T cell zones in secondary 
lymphoid organs thus bringing the B cell in closer proximity to T cells (Reif et al., 2002).  
In addition, BCR binding also upregulates costimulatory molecules such as CD86 and 
CD80 which help the B cell stimulate CD4 helper cells (Lenschow et al., 1994).  
Activated B cells also upregulate CD40 which binds to CD154 on activated T cells (Lee 
et al., 2003).  Not all B cells require T cell help.  Some antigens have been shown to 
activate B cells in the absence of T cell help, but in conjunction with other activating 
signals such as Toll-like receptor (TLR) binding and extensive BCR-crosslinking of 
repetitive epitopes (Vos, 2000).      
The germinal center response  
Activated B cells can follow several different paths.  They can become rapidly 
dividing plasmablasts that downregulate their surface immunoglobulin and produce 
secreted antibodies, they can become plasma cells that secrete even larger quantities of 
Ab, or they can become memory B cells (MBCs).  Activated B cells can also enter 
germinal centers, where they can either die or give rise to MBCs or plasma cells.  
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Germinal centers are located in peripheral lymphoid organs.  The established 
germinal center is polarized into two zones: the light zone and the dark zone (Röhlich, 
1930).  The dark zone is commonly associated with increased cell proliferation, somatic 
hypermutation, and class switch recombination resulting in a greater diversity of Ab 
specificities (Jacob et al., 1991b; Muramatsu et al., 2000; Victora et al., 2010).  However, 
germinal center B cells can also divide in the light zone which is characterized by the 
presence of additional cell types such as follicular dendritic cells (FDC), follicular helper 
T cells (TFH), and macrophages (Allen et al., 2007).  It is thought that high affinity Abs 
are preferentially selected in the light zone by competing for antigen presented on FDCs 
and/or competing for help from TFHs and that this results in enhanced proliferation and 
survival (Anderson et al., 2009; Gitlin et al., 2014).  In addition to competing with other 
clones for antigen, individual cells may also need to compete with secreted Ab for 
particular epitopes, thus raising the bar for high affinity clones (Zhang et al., 2013).  
MBCs emerging from a germinal center response can be long-lived and quiescent until 
reactivated (Jacob et al., 1991a; Toyama et al., 2002).   
While the mechanism for B cell fate determination is not yet clear, recent studies 
have demonstrated that the kinetics of MBCs and long-lived plasma cell development in 
the germinal center differ.  Using bromodeoxyuridine (BrdU) labeling at different time 
points during a germinal center response, it has been determined that the majority of 
MBCs arise from divisions occurring during the early germinal center response, whereas 
most long-lived plasma cells arise from divisions occurring later on in the response 
(Weisel et al., 2016).  In addition, destruction of germinal centers at an intermediate time 
point of the response by anti-CD154 Ab administration has a greater effect on the long-
lived plasma cell population than on the MBC population (Weisel et al., 2016).  These 
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findings suggest that while the germinal center selects for high affinity clones over time, 
it also produces a greater diversity of MBC specificities early on.  
Memory B cell responses 
MBCs can be long-lived and remain quiescent in the absence of antigen 
(Maruyama et al., 2000).  However, upon antigen stimulation, MBCs can rapidly become 
activated and can differentiate into Ab secreting plasma cells or reenter a germinal 
center (Deenick et al., 2013; McHeyzer-Williams et al., 2015).  MBCs can be divided into 
subsets by several criteria and these subsets of MBCs appear to be poised to follow 
different fates upon reactivation.  When divided by isotype, IgM+ MBCs are more likely 
to reenter germinal centers whereas IgG+ MBCs are more likely to differentiate into Ab 
secreting plasma cells (Dogan et al., 2009).  MBCs can also be divided into subsets 
based on their expression of CD80 and PD-L2 with double positive MBCs (CD80+, PD-
L2+, predominantly but not exclusively IgG+) more likely to differentiate into Ab secreting 
plasma cells, and double negative MBCs (CD80-, PD-L2-, predominantly IgM+) more 
likely to form germinal centers (Zuccarino-Catania et al., 2014). Interestingly, the double 
negative MBC subset generally also has a lower degree of somatic mutation (Tomayko 
et al., 2010), suggesting that MBCs with less somatic mutation are more likely to enter 
germinal centers and may be precursors of the higher affinity double positive MBC 
subset.  While it has been shown that the proportion of these MBC subsets is affected by 
precursor frequency, how the mode of exposure or the pathogen itself affects the overall 
makeup of the MBC compartment remains to be determined (Tomayko et al., 2010).  
This could have implications for the quality and kinetics of MBC responses as well as for 
the degree of Ab evolution over time. 
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MBCs have advantages over naïve B cells in their sensitivity to reactivation, 
proliferation, higher precursor frequency, and reduced requirement for T cell help.  There 
are many intrinsic differences between naïve and MBCs that may contribute to a larger, 
more rapid Ab response during a secondary exposure (Tomayko et al., 2008).  Human 
MBCs express higher levels of costimulatory molecules such as CD80 and CD86, which 
may lead to enhanced stimulation during a secondary response (Liu et al., 1995).  MBCs 
also initiate proliferation more rapidly and more frequently upon antigenic stimulation 
than naïve B cells (Tangye et al., 2003).  In addition the increased proportion of class-
switched B cell clones in the MBC repertoire may affect the quality of the recall 
response; studies comparing B cell clones with identical specificities but different 
isotypes demonstrate that the IgG membrane tail increases Ab production and clonal 
expansion and reduces cell loss (Martin and Goodnow, 2002).   As a primary response 
expands clonal populations of antigen-specific B cells, antigen-specific MBCs are also 
present at a higher precursor frequency than naïve B cells (Burnet, 1957; Tas et al., 
2016).  Finally, while T cell-dependent MBCs specific for soluble monomeric antigens 
appear to require T cell help for additional differentiation, virus-specific MBCs have been 
shown to differentiate into plasma cells in the absence of T cell help (Hebeis et al., 2004; 
Hilbert et al., 1989).  
Influenza virus  
Influenza viruses are enveloped single-stranded negative sense RNA viruses 
with 8 RNA segments (McGeoch et al., 1976).  The segmented nature of the viral 
genome is important, as reassortment of RNA segments from 2 or more strains can 
occur (Marshall et al., 2013).  Reassortment can lead to the development of a new 
subtype of influenza virus which, when infecting humans, can result in an antigenic shift.  
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The envelope surface proteins include hemagglutinin (HA), neuraminidase (NA), and M2 
proteins (Lamb et al., 1985).  HA is a homotrimer initially synthesized as the precursor 
HA0 but is further cleaved into two subunits, HA1 and HA2, which remain linked by 
disulfide bonds (Klenk et al., 1975; Lazarowitz and Choppin, 1975; Skehel and 
Waterfield, 1975).  Once cleaved, HA aids in viral attachment and entry into a cell.  It 
binds to sialic acids linked to galactose by predominantly 2-3 or 2-6 linkages.  The 
frequency of these different types of linkages in different species is thought to contribute 
to infectivity of viral strains in different species (Ibricevic et al., 2006; Matrosovich et al., 
2000).  Upon viral uptake by endocytosis, a drop in pH in the endosome induces a 
structural change in the HA which allows the viral membrane to fuse with the endosomal 
membrane, allowing the contents of the virion to be released into the cytosol (Gray and 
Tamm, 1998).  NA aids in viral release by cleaving sialic acid linkages thus preventing 
the HA of newly formed virions from remaining bound to the infected cell (Palese et al., 
1974).  M2 is a proton-selective ion channel that is thought to control the pH of the virion 
in the endosome before membrane fusion, and also in the golgi apparatus to maintain 
HA conformational stability (Takeda et al., 2002; Takeuchi and Lamb, 1994).  It also 
binds to the M1 protein, affecting virion structure, and is required for influenza virus 
induced inflammasome activation (Ichinohe et al., 2010; McCown and Pekosz, 2006).   
Most influenza virus neutralizing Abs bind the HA protein and neutralize either by 
blocking attachment, preventing fusion, or mediating other Ab mediated mechanisms of 
protection such as antibody-dependent cell-mediated cytotoxicity (ADCC) (DiLillo et al., 
2014; Ekiert et al., 2009; Knossow et al., 2002).  However, due to the influenza virus’s 
error-prone polymerase, and the mutational permissiveness of HA, mutations can rapidly 
become fixed in the circulating viral population.  This gradual accumulation of mutations 
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over time is known as antigenic drift.  The membrane distal HA head domain (in contrast 
to the more membrane proximal stalk or stem domain) is particularly permissive of 
mutation and these mutations can significantly affect the binding of previously elicited 
Abs (Heaton et al., 2013).  Because of this loss in Ab specificity, a previously protected 
individual can become susceptible to newly drifted strains of influenza virus.  In addition, 
HA mutations not only affect the antigenic properties of the HA, but also its affinity for 
sialic acid (Hensley et al., 2009). 
Influenza virus surveillance and vaccine strain selection 
As influenza viruses are constantly acquiring mutations, new mutant strains that 
abrogate Ab binding in at least a subset of the human population can arise and supplant 
circulating strains that are more easily neutralized by preexisting immunity.  To monitor 
these constant changes, the World Health Organization (WHO) has developed a 
surveillance system known as the Global Influenza Surveillance and Response System 
(GISRS) (formerly known as the Global Influenza Surveillance Network or GISN).  In this 
system, thousands of viral isolates collected from influenza virus infected individuals are 
screened for their genetic and antigenic properties.  To determine whether a virus is 
antigenically distinct compared to previously circulating strains, the clinical isolates are 
tested by hemagglutination inhibition assay (HAI).  The HAI assay tests the ability of 
antisera to inhibit influenza virus’s ability to hemagglutinate red blood cells.  The antisera 
used in these screens are primarily collected from ferrets that were infected with the 
previously circulating strain, or in more limited cases antisera collected from humans are 
used.  The WHO makes recommendations on which strains should be included in the 
next vaccine based on whether or not the antisera elicited by the previous year’s vaccine 
are still able to inhibit hemagglutination mediated by the new isolate.  The WHO also 
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considers results from microneutralization assays completed with a subset of clinical 
viral isolates.  These assays measure neutralizing Abs against both the HA head and 
stalk (Network, 2011). 
Original Antigenic Sin 
Studies of influenza virus-specific Abs in human sera demonstrate that the Ab 
repertoire differs among different age groups and that the specificity of human sera is 
skewed toward those strains that would have circulated when an individual was a child 
(Davenport and Hennessy, 1956; Davenport et al., 1953; de St.Groth and Webster, 
1966a; Francis, 1955).  This has been recapitulated in multiple animal models (de 
St.Groth and Webster, 1966b; Kim et al., 2009; Virelizier et al., 1974; Webster, 1966).  
As structural analogues can recall previously elicited B cell clones (Deutsch et al., 1973; 
Eisen, 1969), it has been hypothesized that B cell clones specific for the initial strain are 
recalled by antigenically related strains experienced later in life (de St.Groth and 
Webster, 1966a; Li et al., 2013; Wrammert et al., 2011).  However, Abs expressed by B 
cell clones recalled by a structural analogue frequently bind with a higher affinity to the 
priming antigen (Eisen, 1969).  Though these B cell clones are often cross-reactive (de 
St.Groth and Webster, 1966b; Eisen, 1969; Fish et al., 1989; Webster et al., 1976), this 
observation was termed original antigenic sin (OAS) as the Abs expressed by the 
recalled clones have a higher affinity for past strains while the magnitude of strain-
specific Ab titers specific for the more recent strain is frequently reduced (Francis, 1955).  
This reduction in strain-specific Ab titers to the more recent strain can be limited in a 
number of ways.  For instance, while sequential infection with live virus leads to a 
reduction in strain-specific Ab titers that are specific exclusively for the more recent 
strain, sequential vaccination with inactivated virus does not result in an Ab titer 
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reduction (de St.Groth and Webster, 1966b; Kim et al., 2009).  Whether this is due to a 
difference in dose, or due to a difference in the site of exposure is not yet understood.  It 
is clear however, that the viral titers after a secondary infection are often lower in 
animals pre-exposed to antigenically drifted strains, suggesting that cross-reactive 
protection that reduces viral titers to the newer strain most likely contributes to a 
reduction in a novel Ab response (Kim et al., 2009).  Many aspects of OAS might 
therefore simply result from decreased antigen loads during secondary exposures.  
Evidence for OAS in other model systems 
 OAS has also been described in other systems using structurally related 
antigens.  The haptens arsanilic acid and sulfanilic acid are two such structural 
analogues.  While immunization with arsanilic acid elicits the dominant expression of 
Abs encoded by a particular heavy chain variable region, immunization with sulfanilic 
acid does not elicit the expansion of these B cell clones unless mice have been primed 
with arsanilic acid.  Additionally, these Abs bind with a higher relative affinity to arsanilic 
acid than to sulfanilic acid (Fish et al., 1989).  OAS has also been described after 
sequential exposure to serologically distinct variant bacterial strains (termed serovars).  
Studies describing sequential exposure to different serovars of Chlamydia trachomatis 
demonstrate a boost in Ab titers to the priming serovar, an increase in cross-reactive 
serum titers, and an altered Ab repertoire after heterologous exposure (Berry et al., 
1999).  OAS has also been demonstrated after sequential exposure to different subtypes 
of dengue virus and is also hypothesized to play a role in the evolution of the antibody 
response to HIV (Ciupe et al., 2011; Halstead et al., 1983).  
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 An OAS-like phenomenon has also been described for cytotoxic T lymphocytes 
(CTLs) in response to sequential infection with variant strains of lymphocytic 
choriomeningitis virus (LCMV), dengue virus, and HIV (Klenerman and Zinkernagel, 
1998; Mongkolsapaya et al., 2003; Ueno et al., 2007).  In the cases of LCMV and 
dengue virus, activated CTLs are found to be directed against the priming strain rather 
than a new variant.  In the case of HIV, the variant-specific CTL population expands but 
has reduced cytotoxic activity compared to CTLs specific for the priming strain.  
Development of universal influenza vaccines with sequential exposure strategies. 
According to the doctrine of OAS, the Ab repertoire is skewed towards clones 
that have been previously elicited by earlier circulating strains.  This has been thought to 
result in both positive and negative effects.  On the one hand, it can skew the Ab 
repertoire to more conserved sites.  Should these conserved sites be broadly conserved 
and maintained, due to structural or functional constraints, Abs specific for these sites 
have the potential to be more broadly cross-reactive and may provide protection against 
a broader repertoire of viral strains.  On the other hand, should the Ab response be 
shifted to epitopes that are not neutralizing or that are not broadly conserved, this could 
reduce protection against other strains.  In addition, the reduction in Ab titers specific for 
newly formed epitopes can reduce protection against newly drifted strains.  Shifting Ab 
immunodominance to highly conserved sites is the target of several experimental 
vaccine regimens designed to broaden and increase protection against rapidly mutating 
and diverse viral populations (Krammer et al., 2013; Malherbe et al., 2011; Wang et al., 
2010; Wei et al., 2010).  While sequential vaccination has been successfully used to 
increase the proportion of Abs elicited to conserved regions of the HA, this has been a 
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transient effect that is lost upon re-exposure to an antigenically related strain (Andrews 
et al., 2015; Ellebedy et al., 2014).  
Antigenic properties of influenza hemagglutinin and the description of antigenic 
sites. 
The earliest documented way of experimentally determining if two influenza virus 
strains were antigenically similar was to test if one strain elicited a protective response 
against another, either by challenging pre-infected ferrets with a second strain, or by 
incubating a viral strain with antisera collected from previously infected ferrets or 
humans and then testing its infectivity (Smith et al., 1933).    
With the discovery of the hemagglutination property of influenza viruses, the HAI 
assay became a widespread method for testing the degree of antigenic difference (Hirst, 
1941).  Unfortunately, as the HAI assay only measures the ability of serum to inhibit 
influenza virus’s ability to hemagglutinate red blood cells, it only measures the subset of 
the Ab repertoire that inhibits hemagglutination.  For example, stalk-specific Abs as well 
as select Abs specific for the HA head domain fail to inhibit virus mediated 
hemagglutination, and are therefore not measured by the HAI assay. However, this was 
not apparent during early studies of the influenza antibody response, as the binding 
footprints of HA-specific Abs and their effect on hemagglutination as well as 
neutralization were unknown. 
Several approaches were taken to determine the regions of the HA where 
antibodies bind, otherwise known as the antigenic sites of HA.  The structure of the H3 
HA from A/Hong Kong/1968 was solved in 1980 (Wilson et al., 1981).  Using sequences 
of previously circulating H3N2 viruses as well as laboratory variants that had been 
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isolated after incubation with monoclonal antibody (mAb) or most-avid-fraction Ab, amino 
acids that differed between isolates were mapped to the HA structure (Wiley et al., 
1981).  The combination of the sequence and structural data led to the description of 4 
different antigenic regions of the A/Hong Kong/1968 H3 HA (A, B, C, and D).  Not all 
mutations were considered to be antigenically relevant with some characterized as 
antigenically neutral based on their location on the HA structure.  A mutation may be 
antigenically neutral as any mutation may be positively selected for enhanced viral 
fitness or structural stability independent of Ab binding, or may accumulate due to the 
stochastic nature of viral mutation. In addition, some mutations, particularly those 
located at the interface of the HA subunits, may indirectly affect Ab binding by altering 
more distant epitopes, and may therefore not be in an antibody footprint themselves.  
However, this does not preclude the possibility that apparently neutral mutations may be 
antigenically relevant in a different context, such as in individuals with different antibody 
repertoires or due to the loss of a glycosylation site (Skehel et al., 1984). As this process 
of delineating antigenic sites depends on mapping HA mutations, it may also overlook 
residues in potential antibody footprints that are functionally constrained and therefore 
not mutated in infectious virus, or non-neutralizing Abs that do not positively select for 
HA mutations. 
The H1 HA antigenic sites were initially mapped differently.  Rather than mapping 
mutations directly to the HA structure and dividing these into different regions based on 
structural components, viral mutants isolated after incubation with neutralizing mAb were 
grouped based on the binding characteristics of a panel of virus-specific mAbs 
developed after primary or secondary exposure to A/Puerto Rico/08/1934 (PR8) in 
BALB/c mice (Gerhard et al., 1981).  Viral mutants that abrogated binding of a particular 
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set of mAbs were grouped separately from viral mutants that bound to those mAbs but 
failed to bind to others.  Four antigenic sites were initially assigned based on antibody 
binding rather than topology.  These were known as the Sa, Sb, Ca, and Cb sites.  
These are not necessarily discrete sites, as some mAbs overlapped multiple antigenic 
sites (Gerhard et al., 1981; Lubeck and Gerhard, 1981).  Once the viral mutants in each 
antigenic site were sequenced and mapped to the H3 HA structure, the antigenic sites 
were found to group together in different topographically distinct regions of the HA head 
group with the Sa and Sb sites located on the distal end of the head and the Ca (further 
subdivided into the Ca1 and Ca2 subgroups) and Cb sites located more proximally to the 
membrane (Caton et al., 1982).  
Recent advances in sequencing technology have aided the continued description 
of HA antigenic sites.  Antigenicity of particular residues as described by potential codon 
bias towards diversification, positive selection of amino acids, and entropy and likelihood 
ratios in large cohorts of HA sequences have correlated with the previously described 
antigenic sites, but new potential antigenic residues have also been identified (Bush et 
al., 1999; Huang et al., 2012; Plotkin and Dushoff, 2003).  In addition, co-crystallizations 
of mAb bound to HA has elucidated new binding sites, particularly in highly conserved 
regions where mutations are rare or impossible due to functional constraints (Dreyfus et 
al., 2013).  This is of particular importance to the understanding of antigenic sites as Abs 
that bind to highly conserved, rarely mutated sites are potentially broadly neutralizing 
and may protect against a wider diversity of strains despite antigenic drift.  The original 
naming schemes of the antigenic sites described for the A/Hong Kong/1968 and PR8 HA 
are often appropriated for other viral strains, and new naming schemes for particular 
strains have been proposed (Huang et al., 2012).  However, caution should be exercised 
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when applying these defined antigenic sites to new strains as the HA structure has 
evolved over time, and our understanding of HA antigenicity continues to advance. 
B cell Immunodominance 
While most PR8-specific mAbs can be mapped to the dominant antigenic sites 
previously mapped on the HA head domain, the site dominance differs between the 
early primary and secondary responses.  For instance, approximately 50% of the early 
primary mAbs in BALB/c mice are specific for the Cb site and many of these mAbs share 
a limited set of light and heavy chain regions (Kavaler et al., 1990).  However, these 
clones (that can be recognized by an Ab specific for a light chain-associated idiotope 
known as 23-1 Id) are not recalled by a secondary exposure (Kavaler et al., 1991).  Why 
this particular set of epitopes is immunodominant in the primary response and not after a 
secondary response is not known.  More recent studies on this particular specificity 
suggest that the early PR8 Cb response relies predominantly on extrafollicular 
responses, although low numbers of 23-1 Id+ cells with germinal center markers 
(CD45Rhi CD38lo CD24hi) are also evident (Rothaeusler and Baumgarth, 2010).   
Why epitopes of the HA head are more immunodominant than more conserved 
epitopes located in the stalk region of the HA is unknown.  Some have hypothesized that 
the subdominance of stalk epitopes may be due to steric hindrance as viral glycoproteins 
are clustered together tightly at the viral surface.  This steric hindrance is maintained 
when HA is solubilized by bromelain mediated cleavage from the membrane as the HA 
molecules aggregate and form rosettes (Kawasaki et al., 1983).  Interestingly, recent 
research in lampreys has shown that even the structurally unrelated variable lymphocyte 
receptor B (VLRB) response is targeted towards the HA head when these jawless 
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vertebrates are immunized with inactivated influenza virus (Altman et al., 2015).  The 
immunodominance of the HA head region is therefore not immunoglobulin or species 
specific, but may rather be due to some inherent chemical or structural components.  
Multiple strategies to overcome subdominance have been proposed, from sequential 
vaccination as described above, to expanding the B cell repertoire by adding adjuvants 
to the immunogen (Clegg et al., 2012; Goff et al., 2013; Khurana et al., 2011a).    
Experimental Questions 
The theory of OAS is somewhat paradoxical to the theory of B cell clonal 
selection as it posits that antigenically drifted strains of influenza recall B cell clones 
specific for an earlier circulating strain that are not well adapted for the present strain.  
While this has been documented in both humans and various animal models, the fine 
specificity of OAS Abs that have a higher affinity for the priming antigen than the recall 
antigen, and their potential role in protection against the current strain have not been 
carefully described.  We address this question in chapter two by sequentially immunizing 
mice with antigenically drifted strains of influenza.  We analyze mouse sera, and 
generate hybridomas from sequentially immunized mice.  We map the fine specificities 
of the mAbs derived from these hybridomas by testing their binding by ELISA to a large 
panel of mutant viruses to determine how pre-exposure history affects the specificity of 
the Ab repertoire.  To determine the role of OAS Abs in protection against the 
contemporary influenza strain, we test the ability of mAbs to neutralize influenza virus 
infection in vivo by passive transfer experiments in mice.  Our data suggest that the 
threshold of cross-reactivity required to recall B cell clones that are specific for previous 
strains is low, but that it has an effect on the fine specificity on the Abs that are recalled 
and that these OAS Abs contribute to protection against an antigenically drifted strain.  
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This is important, as it changes our understanding of OAS and how the Ab repertoire is 
affected by sequential exposure to influenza viruses.       
In chapter three, we complete a series of experiments to determine how previous 
influenza exposures shape human Ab responses against new viral strains.  It has been 
shown that individuals from different age groups can have Ab repertoires that are 
focused on different antigenic sites and this is hypothesized to be due to different 
influenza virus pre-exposure history (Davenport et al., 1953).  We hypothesize that this 
might contribute to age group specific susceptibility to influenza strains that have 
acquired mutations that abrogate binding of Abs prevalent in a particular age group.  In 
the 2013-2014 influenza season, middle-aged adults were affected by an unusually high 
influenza disease burden.  We hypothesize that this is due to the recent acquisition of a 
mutation that abrogates binding to Abs prevalent in middle-aged adult sera.  To test this 
theory, we analyze human sera from healthy human blood donors, humans vaccinated 
with the A/California/07/2009 strain (pH1N1), and ferrets sequentially infected with 
circulating H1N1 strains. These experiments not only address questions regarding 
current influenza surveillance methodology, but also contribute to our understanding of 
how influenza repertoire differences in humans affect protection to antigenically drifted 
circulating strains of influenza.       
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CHAPTER 2: ‘ORIGINAL ANTIGENIC SIN’ ANTIBODIES ARE A 
VALUABLE COMPONENT OF SECONDARY IMMUNE 
RESPONSES TO INFLUENZA VIRUSES 
Summary 
Human Abs elicited by influenza viruses often bind with a high affinity to past 
influenza virus strains, but paradoxically, bind poorly to the viral strain actually eliciting 
the response.  These Abs have been referred to as ‘original antigenic sin’ Abs.  Using a 
mouse model, we find that OAS and non-OAS Abs target the same general region of the 
influenza HA and that somatic hypermutation can modify the degree of cross-reactivity of 
OAS Abs.  Surprisingly, although OAS Abs bound with very low affinities, some were 
able to effectively neutralize an antigenically drifted viral strain following passive transfer 
in vivo.  Taken together, our data indicate that OAS Abs share some level of cross-
reactivity between priming and recall viral strains and that these Abs can be protective 
when recalled into secondary immune responses. 
Introduction 
Influenza viruses continuously acquire mutations in antigenically important 
regions of the HA and NA proteins through a process termed ‘antigenic drift’.  Single HA 
mutations can dramatically reduce Ab recognition of influenza viruses (Caton et al., 
1982).  Although influenza infections lead to strain-specific lifelong immunity (Yu et al., 
2008), humans are routinely re-infected with antigenically drifted influenza strains 
throughout life.  Most humans are infected with seasonal influenza viruses by 3 years of 
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age (Bodewes et al., 2011) and then re-infected with antigenically drifted strains every 5-
10 years (Kucharski et al., 2015).   
Influenza infections early in life can leave long-lived immunological imprints. In 
1960, Thomas Francis coined the term ‘original antigenic sin’ to describe the observation 
that Abs primed by older viral strains often dominate secondary responses elicited by 
new antigenically drifted viral strains (Francis, 1960).  The ‘S’ in OAS refers to the 
observation that the recall of Abs generated against past strains can occur at the 
apparent expense of generating de novo Abs that react to new viral strains (de St.Groth 
and Webster, 1966a; Francis, 1960).  It is thought that OAS Abs are detrimental to the 
host since they react poorly to the viral strain that is actually recalling them.  
While it is clear that the majority of human influenza infections take place in the 
context of a previously exposed host, most animal models do not take prior-exposures 
into account.  Recently, Jacobs and colleagues established a mouse model of OAS (Kim 
et al., 2012; Kim et al., 2009).  These studies show that OAS Abs can be elicited in mice 
following sequential exposures with antigenically distinct influenza strains.  Here, we 
used a similar mouse model to determine the precise binding footprints and 
neutralization efficiencies of OAS Abs elicited by sequential influenza exposures.  
Surprisingly, we found that many OAS Abs target the same general region of HA that is 
recognized by non-OAS Abs.  Further, we found that OAS Abs can be highly effective at 
neutralizing antigenically distinct viruses in vivo and that B cells producing OAS Abs are 
clonally related to B cells that produce non-OAS Abs.  Taken together, our data suggest 
that OAS Abs are a valuable protective component of secondary influenza immune 
responses.  
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Results 
Establishment of a mouse model of ‘OAS’ 
We established a mouse model to determine how prior H1N1 influenza A virus 
exposures influence the generation of new Ab responses against antigenically drifted 
H1N1 strains.  For these studies, we utilized the well-characterized A/Puerto 
Rico/8/1934 (PR8) and A/Puerto Rico/8/1934-S12a (S12a) H1N1 strains (Caton et al., 
1982; Das et al., 2013; Gerhard et al., 1981).  Early mAb mapping studies demonstrated 
that there are 4 dominant antigenic sites on the globular head region of the HA of PR8 
(Gerhard et al., 1981).  The HAs of PR8 and S12a differ by 13 mutations spread across 
the 4 dominant HA head antigenic sites (Figure 1A) (Caton et al., 1982; Das et al., 
2013).  PR8 and S12a viruses are antigenically distinct as determined by HAI assays 
(Figure 1B-C), which measure Ab inhibition of virus binding to red blood cells.  Although 
the HA stalk region of these viruses is identical (Figure 1A), 98% of PR8-elicited mAbs 
fail to recognize a virus closely related to the S12a virus in direct binding assays (Das et 
al., 2013).  
We exposed mice to the PR8 virus and then re-exposed the same mice 28 days 
later with the identical PR8 virus or the antigenically distinct S12a virus.  Initial viral 
exposures were given via the intraperitoneal (i.p.) route and secondary exposures were 
given via the intravenous (i.v.) route.  Secondary exposures were delivered via the i.v. 
route to enhance our ability to derive hybridomas from sequentially exposed mice. 
We first measured PR8-reactive Abs in sera collected from these mice.  As 
expected, PR8-reactive Abs were boosted upon re-exposure with PR8 (Figure 2A).  
Surprisingly, the antigenically distinct S12a virus was also able to boost PR8-reactive 
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Abs to levels comparable to those elicited by a homologous PR8-PR8 prime-boost 
(Figure 2A).  This boosting of the PR8 response was not due to non-specific activation of 
B cell clones initiated by the first viral exposure, since an influenza B strain (B/Lee/1940; 
unrelated to the PR8 and S12a H1N1 influenza A strains) did not boost PR8 Abs in mice 
originally exposed to PR8 (Figure 2A).  Similar results were obtained when we exposed 
mice with S12a virus 70 days after the initial PR8 exposure (Figure 3A).  Since HAI 
assays only detect Abs directed against the globular head of HA, we completed 
additional direct ELISA binding assays.  Consistent with our HAI data, PR8-reactive Abs 
detected by ELISA (which measure head and stalk HA Abs) were similar in sera 
collected from mice sequentially exposed to PR8 twice and mice sequentially exposed to 
PR8 and the antigenically distinct S12a virus (Figure 3B). 
Classically, OAS describes the process by which B cells stimulated by past viral 
exposures dominate and suppress the generation of de novo activated B cells that 
recognize new antigens present in drifted viral strains (Francis, 1960).  To determine if 
PR8 pre-exposure prevents the generation of de novo Ab responses capable of 
recognizing S12a, we measured levels of S12a-reactive Abs in sequentially exposed 
mice.  Similar levels of S12a-reactive Abs were present in S12a exposed mice with or 
without prior PR8 exposure (Figure 2B).  Taken together, our data suggest that in PR8-
exposed mice, S12a elicits Abs that react to the antigenically distinct PR8 strain but that 
this does not occur at the expense of eliciting S12a-reactive Abs. 
Identification of OAS Abs 
Our experiments using sera cannot distinguish whether cross-reactive Abs are 
preferentially elicited in sequentially exposed mice or if PR8-specific Abs and S12a-
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specific Abs are both elicited in sequentially exposed mice.  To determine the specificity 
of Abs elicited in our experimental system, we created a panel of 289 hybridoma cell 
lines from mice exposed to only PR8, to only S12a, sequentially to PR8 twice, or 
sequentially to PR8 and S12a (Figure 4).  Hybridoma cell lines were created from a total 
of 23 mice (Figure 5).  Consistent with previous studies (Das et al., 2013), a single PR8 
exposure elicited mAbs that bound with a high affinity to PR8 but not S12a (Figure 4A).  
Likewise, the majority of mAbs elicited by a single S12a exposure bound with a high 
affinity to S12a but not to PR8 (Figure 4B).  Most mAbs elicited by PR8-PR8 sequential 
exposure bound with a high affinity to PR8 and not S12a, although some mAbs elicited 
under these conditions were able to bind to both viruses (Figure 4C).  Sequential 
exposure with PR8 and S12a elicited a higher proportion of mAbs that were able to bind 
with a high affinity to both PR8 and S12a (Figure 4D; p < 0.05; Fisher’s exact test).  
Almost all of these cross-reactive mAbs bound to PR8 better than to S12a (sample 
binding curves shown in Figure 6).  S12a-specific mAbs were also elicited by PR8-S12a 
sequential exposure (Figure 4D).  Strikingly, approximately half of the mAbs elicited by 
sequential exposure to PR8 and S12a bound with a high affinity to PR8 and not S12a 
(Figure 4D).  Most of these ‘OAS’ mAbs bound to S12a so poorly that actual binding 
affinities to S12a could not be calculated using standard ELISA assays (Figure 7).  As a 
control, we attempted to create hybridoma cell lines from PR8-exposed mice that were 
subsequently exposed to an unrelated influenza B strain.  We were unable to isolate 
PR8-reactive mAbs under these conditions, which indicates that some level of antigenic-
relatedness is required to recall PR8-reactive Abs in PR8 pre-exposed mice.    
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Specificity and functionality of OAS Abs 
We mapped the binding footprints of each mAb by measuring binding to a large 
panel of PR8 viruses that possessed single mutations in the HA (Figure 8).  Our mutant 
PR8 viral panel included previously characterized mAb escape mutants (Caton et al., 
1982), as well as new escape mutants that we isolated after incubating PR8 virus with 
mAbs from this study (for example, the K189N HA mutant was isolated after growing 
PR8 virus in the presence of the H5-60A mAb).  We tested mAb binding to viruses that 
possessed single mutations across the 4 dominant HA antigenic sites (Sa, Sb, Ca, and 
Cb).  The majority of mAbs isolated from mice sequentially exposed to PR8-PR8 and 
PR8-S12a did not bind to PR8 viruses possessing Sb mutations (Figure 8A-B, Figure 9), 
indicating that both PR8-PR8 and PR8-S12a sequential exposures elicit an Ab response 
that is immunodominant against epitopes in the Sb antigenic site of HA.  Approximately 
½ of the Sb mAbs isolated from mice sequentially exposed to PR8 and S12a displayed a 
classical OAS phenotype since they bound poorly to S12a (Figure 8B).  Importantly, the 
other ~ ½ of the Sb mAbs isolated from mice sequentially exposed to PR8 and S12a 
were cross-reactive with strong binding to both PR8 and S12a (Figure 8B).  mAbs 
isolated from mice receiving only a single PR8 or S12a exposure reacted to all 4 HA 
globular head antigenic sites and were not as frequently directed against the Sb 
antigenic site (Figure 9), indicating that sequential viral exposure focused the Ab 
response towards the Sb antigenic site.  
We next sought to determine if there are fine specificity differences that 
distinguish Sb mAbs isolated from mice exposed with PR8-PR8 compared to PR8-S12a.  
To do this, we completed additional mAb binding experiments with a larger panel of PR8 
viruses with single Sb mutations (Figure 10).  There was a notable key difference in the 
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binding footprint of Sb mAbs isolated from mice sequentially exposed to PR8-PR8 
compared to PR8-S12a:  the majority (70%) of Sb mAbs isolated from mice sequentially 
exposed twice with PR8 failed to bind to viruses with a mutation at HA residue 156, 
whereas the minority (20%) of Sb mAbs isolated from mice sequentially exposed with 
PR8 and S12a were sensitive to the 156 mutation (Figure 11A-B and Figure 10).  This is 
important because the Sb antigenic site of PR8 and S12a differ at residue 156 (PR8 has 
E156 and S12a has K156).  Most of the ‘OAS’ Sb Abs that were elicited by PR8-S12a 
sequential exposure did not bind to PR8 viruses with an E156K HA mutation (these Abs 
had a similar footprint to most Sb Abs elicited by PR8-PR8 sequential exposure), 
whereas most of the cross-reactive Sb Abs elicited by PR8-S12a sequential exposure 
were less affected by the E156K mutation (Figure 8B and Figure 10).   
To determine if mAbs isolates from mice sequentially exposed to PR8 and S12a 
can protect against viral infection, we completed a series of passive transfer studies in 
mice.  We transferred mAbs that were either sensitive (H2-S37B) or resistant (H4-S10B) 
to the E156K HA mutation and we then challenged mice with either PR8 or S12a virus.  
Both mAbs protected mice against PR8 infection (Figure 11C).  The H2-S37B mAb that 
was sensitive to the PR8 E156K HA mutation failed to protect mice against the S12a 
virus, however the H4-S10B mAb that was resistant to the PR8 E156K HA mutation fully 
protected mice against the S12a virus (Figure 11D).  The E156K-resistant mAb was able 
to protect against S12a virus infection, despite binding to S12a with a much lower affinity 
compared to PR8 (Figure 8B).  
These data suggest that sequential exposure with PR8 and S12a elicit two 
closely related but clearly distinct types of Sb-specific Abs.  The first type of Ab displays 
a classical OAS phenotype in that these Abs have minimal cross-reactivity to S12a or a 
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PR8 virus engineered to have the E156K HA mutation, which is the mutation that is 
largely responsible for the Sb antigenic difference between PR8 and S12a.  The second 
type of Ab targets the same general Sb region but binds strongly to both PR8 and S12a 
and is not sensitive to variation at residue 156.  These cross-reactive Abs appear to 
have a narrower binding footprint based on our binding assays using a large panel of Sb 
mutant PR8 viruses (Figure 10).   
Somatic mutations affect the cross-reactivity of Sb mAbs 
In an attempt to identify clonally related mAbs, we sequenced the heavy and light 
chains of a number of our hybridoma cell lines.  We identified a group of 6 clonally 
related IgG2a mAbs derived from a single mouse that was sequentially exposed to PR8 
and S12a (Table 1).  These 6 related mAbs had different binding affinities to PR8 and 
S12a (Figure 12).  For example, the H5-42B mAb had very weak binding to S12a (Figure 
12A), whereas the H5-61B mAb, which differed by only 4 amino acids in the heavy chain 
relative to H5-42B (1 CDR1, 2 FR3, and 1 CDR3 differences), had dramatically 
increased binding to S12a (Figure 12B).  The H5-61B mAb bound better to a PR8 
mutant virus possessing the E156K Sb mutation compared to the H5-42B mAb (Figure 
8).  It is unclear if the mutations that differentiate H5-42B and H5-61B originated during 
the initial priming with the PR8 virus or during the secondary recall response against 
S12a.  Regardless, these data suggest that somatic mutations can influence the level of 
cross-reactivity of Abs elicited by secondary influenza exposures. 
To determine if the H5-42B and H5-61B mAbs have different protective 
efficiencies, we completed in vivo passive transfer experiments.  As an added control, 
we measured HAI titers of sera collected 12 hours after mAb transfer at the time of 
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infection.  Ab titers were not significantly different between mice receiving the H5-42B or 
H5-61B mAbs, and the average HAI titer against PR8 was 50, which is well below the 
average HAI titers of 140 elicited after a primary response to immunization with 1000 
HAU PR8 (Figure 13C).  Both the H5-42B and H5-61B mAbs inhibited PR8 infection 
following passive transfer in vivo (Figure 13A).  Surprisingly, despite the observation that 
H5-42B binds poorly to S12a (Figure 8), both mAbs also inhibited S12a infection 
following passive transfer in vivo (Figure 13B).  The H5-61B mAb, which had a higher 
relative binding affinity to S12a compared to H5-42B, was more protective following 
S12a infection in vivo compared to H5-42B (Figure 13B).  As a comparison, we also 
tested mAbs isolated from mice following a primary PR8 exposure (the H0-P2D5D10 
mAb) or a primary S12a exposure (the H7-S2-2A mAb).  As expected, the PR8 primary 
mAb protected mice only against PR8 infection and the S12a primary mAb protected 
mice only against S12a infection (Figure 13A-B).  Importantly, the S12a primary mAb 
protected mice against S12a infection to the same extent as the H5-42B mAb elicited by 
PR8-S12a sequential exposure.  These data indicate that Abs elicited by sequential 
exposures can be highly effective at neutralizing the virus that recalls them, even though 
they often bind with a much higher affinity to the first viral strain that the host 
encountered.  These Abs can be as effective as Abs elicited in a previously naïve host. 
Discussion 
Most vaccines elicit protective Abs and MBCs that are poised to respond quickly 
to a secondary exposure (Plotkin, 2010).  Formulating effective vaccines against rapidly 
changing pathogens, such as influenza viruses, is challenging (Hensley, 2014; Schultz-
Cherry and Jones, 2010; Stohr et al., 2012).  Influenza vaccines are less effective when 
viruses acquire mutations in Ab binding sites on the HA, as was the case during the 
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2014-2015 influenza season (Chambers et al., 2015). B cells primed against older 
influenza strains are recruited upon exposure with new influenza strains, even when 
major HA antigenic changes have occurred.  For example, prior seasonal H1N1 (sH1N1) 
exposure heavily influenced the types of Abs that were elicited in humans against the 
2009 pandemic H1N1 strain (Li et al., 2012; Li et al., 2013; Linderman et al., 2014; 
Wrammert et al., 2011).  mAbs isolated from humans exposed to the 2009 pH1N1 
recognize epitopes that are conserved on older sH1N1 strains, and these mAbs have a 
high level of somatic mutation indicating that they were likely derived from a memory B 
cell pool (Wrammert et al., 2011).  Immune skewing towards epitopes present in older 
viral strains is likely a result of MBC clones outcompeting naïve B cell clones that are 
specific for epitopes present in new viral strains (Engels et al., 2009; Kometani et al., 
2013; Liu et al., 2012).  In the case of the 2009 pH1N1 strain, many of these cross-
reactive mAbs were protective and so the recall of B cell clones originally primed by 
sH1N1 viruses was likely advantageous to the host. 
There is evidence that prior influenza exposures can negatively affect priming of 
Ab responses against new viral strains through a process commonly called OAS 
(Davenport et al., 1953; Fazekas de St and Webster, 1966; Francis, 1955; Francis, 
1960; Webster, 1966).  Prior influenza exposures can decrease the generation of de 
novo Ab responses, but this is partially due to cross-reactive immunity (originally elicited 
by prior exposures) eliminating antigen following secondary exposure with antigenically 
drifted strains (Kim et al., 2009).  New Ab responses are not primed effectively when 
cross-reactive Abs limit antigen levels.  In this context, prior immunity is again 
advantageous because Abs elicited against prior influenza exposures are partially 
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protective and limit the amount of virus and antigen expressed upon secondary 
exposure.   
A poorly understood component of OAS is that antigenically distinct viruses recall 
some Abs that paradoxically only react to older viral strains and not to the viral strain that 
is actually eliciting the response.  Our data indicate that there are surprisingly only subtle 
differences between OAS and cross-reactive Abs.  We expected that sequential 
exposure with the PR8 and S12a strains would elicit Ab responses directed towards the 
HA stalk, since this region of HA is fully conserved between the two viral strains.  
However, we found that the majority of Abs elicited by PR8-S12a sequential exposure 
were directed against the Sb antigenic site of HA, which differs significantly between the 
two viral strains.  Some Sb-specific mAbs elicited by sequential exposure exhibited a 
classical OAS phenotype in that they bound very poorly to S12a but bound with a high 
affinity to PR8.  Other Sb-specific mAbs elicited in the same mice were more cross-
reactive and bound to both PR8 and S12a.  The most important part of our study is that 
we discovered that both OAS and cross-reactive Sb Abs recognized the same epitope 
within the Sb antigenic site and that cross-reactive Sb Abs were more tolerant of 
antigenic differences within this epitope.  Very few somatic mutations were required to 
increase S12a-reactivity of OAS Abs, indicating that OAS and cross-reactive Abs can be 
clonally related. 
Although OAS Abs are typically thought of as detrimental, OAS Abs elicited in 
our experiments were able to protect mice from S12a infections in passive mAb transfer 
experiments.  This, along with the observation that B cells producing OAS Abs are 
potentially precursors for B cells that produce more cross-reactive Abs, suggests that 
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OAS Abs play an important role in protecting the host against secondary encounters with 
antigenically drifted viral strains.   
Materials and Methods 
Animal Experiments 
All murine experiments were performed at the Wistar Institute according to 
protocols approved by the Wistar Institute Institutional Animal Care and Use Committee.  
All mice were BALB/c strain female mice of at least 7 weeks of age.   
Viruses 
Viruses were grown in 10-day old fertilized chicken eggs and the HA genes of 
each virus stock were sequenced to verify that additional mutations did not arise during 
propagation. S12a has an additional K144E HA mutation compared to the previously 
published Seq12 virus (Das et al., 2013).  Seq12 viruses possessing the K144E HA 
mutation grow efficiently in fertilized chicken eggs without acquiring additional HA 
mutations.  Some virus mutants were generated by reverse genetics as previously 
described (Martínez-Sobrido and García-Sastre, 2010).  Selected mutations were added 
to the HA gene in a pDZ plasmid using a QuikChange II XL site-directed mutagenesis kit 
(Agilent).  As controls, we used B/Lee/1940 and the A/Puerto Rico/08/1934-J1 strain that 
has an H3 HA from A/Hong Kong/01/1968.   
HAU Assays 
To determine the hemagglutination unit (HAU) titer of each viral prep, viruses 
were diluted 2-fold across a 96-well round bottom plate (BD) and mixed with 12.5ul of 
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2% (vol/vol) turkey erythrocytes (Lampire) in phosphate-buffered saline (PBS) (Cellgro).  
Agglutination was read out after incubating for 60 minutes at room temperature. 
50% Tissue Culture Infectious Dose (TCID50) Assays 
96-well flat bottom plates (BD) were incubated overnight with 4e4 Madin Darby 
canine kidney (MDCK) cells/well in minimum essential medium (MEM) (Cellgro) with 9% 
fetal bovine serum (FBS) (Sigma).  Plates were washed 3 times with serum-free MEM.  
Viruses were diluted 10-fold across the plate in MEM supplemented with 0.1% 
gentamicin (Gibco), 1ug/ml L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-
treated trypsin (Worthington), and 5 mM 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) (Cellgro). 
HAI Assays 
Sera were collected from mice by submandibular bleeding into 1.1ml Serum Gel 
Z microtubes (Sarstedt) using a 5 mm lancet (Medipoint).  Sera were then heat treated 
for 30 minutes at 55C.  HAI titrations were performed in 96-well round bottom plates. 
Sera were serially diluted 2-fold in PBS and added to 4 agglutinating doses of virus in a 
total volume of 100 µL. Turkey erythrocytes were added [12.5 µL of a 2% (vol/vol) 
solution]. The erythrocytes were gently mixed with sera and virus and agglutination was 
read out after incubating for 60 min at room temperature. HAI titers are expressed as the 
inverse of the highest dilution that inhibited 4 agglutinating doses of virus.   
ELISA 
Viruses for ELISAs were inactivated by B-Propiolactone (BPL; Sigma-Aldrich) 
treatment.  Viruses were incubated with 0.1% BPL and 0.1 M HEPES overnight at 4C 
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followed by a 90 minute incubation at 37C. 96-well Immulon 4HBX flat-bottom microtiter 
plates (Fisher Scientific) were coated with 20 HAU per well BPL-treated virus overnight 
at 4C.  Plates were then incubated with 150ul 3% bovine serum albumin (BSA) (Sigma) 
in PBS for 2 hours at room temperature.  For initial hybridoma screening, hybridoma 
supernatants were diluted 1:5 and then added to ELISA plates.  For Ab footprint 
mapping, purified mAbs were added at a starting concentration of 1 to 10 ug/ml and 
diluted 2-fold across the plate.  As a positive control, we used the stalk-reactive C179 
mAb (Clontech).  As a negative control and to assure that mAbs bound to HA, we used 
the J1 virus strain which has an H3 HA.  mAbs were incubated on the plates for 2 hours 
at room temperature. mAb binding was measured by a secondary goat anti mouse IgG 
or IgM Ab conjugated to alkaline phosphatase (Southern Biotech) incubated for 1 hour at 
room temperature.  Plates were developed with 100ul/well of a 2.7mM p-nitrophenyl 
phosphate (PNPP) (Thermo Scientific) 0.1M NaHCO3 (Sigma-Aldrich) 1mM MgCl2 
(Fisher Scientific) pH 9.8 solution.  Absorbance was measured at 405nm.  Plates were 
washed with distilled water between each incubation step. 
Hybridoma production 
Some mice were first primed with 1000 HAU of virus with an i.p. injection and 
boosted 28 days later with 1000 HAU of virus with an i.v. injection.  3 days later, 
splenocytes from these mice were fused with SP2/0 cells using Polyethylene glycol 
(Hybrimax 50% (w/v) Sigma-Aldrich).  Some mice were primed only once i.v. with 1000 
HAU of virus and splenocytes from these mice were fused 5 days later.  Fused cells 
were incubated in 5.7uM azaserine and 100uM hypoxanthine (Azaserine-hypoxanthine 
Sigma-Aldrich) with 10% FBS in Dulbecco’s modified eagle medium (DMEM) (Cellgro).  
10 days later hybridomas were screened by ELISA as described above.  Positive clones 
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were subcloned by limiting dilution, and then grown in DMEM supplemented with Zap 
hybridoma (InVitria).  mAbs were purified using PureProteome A/G coated magnetic 
beads (Millipore). For mAb transfer experiments, mAbs underwent buffer exchange into 
PBS using Zeba desalt spin columns (Thermo Scientific). 
mAb transfer experiments 
25 ug of purified mAbs diluted in PBS were transferred into female BALB/c mice 
(Charles River Laboratories) in a 200ul i.p injection. 12 hours later, mice were 
challenged intranasally with a dose of 30 TCID50 of either PR8 or S12a in 50ul PBS.  
For intranasal infections, mice were first anesthetized by inhalation of isoflurane (Henry 
Schein).  Weight was measured daily for 14 days.  
Immunoglobulin sequencing 
DNA was isolated from hybridoma clones using a Gentra Puregene cell kit 
(Qiagen).  Immunoglobulin heavy and light chain genes were amplified by PCR using a 
Platinum Taq DNA Polymerase High Fidelity kit (Thermo Fisher Scientific) using 
previously described primers (Ramsden et al., 1994; Wang et al., 2000).  Amplified DNA 
was run on a 1% agarose (Lonza) in TAE buffer (Corning) gel and DNA was purified 
from the gel using a Zymoclean gel DNA recovery kit (Zymo Research).  DNA fragments 
were then sequenced by Sanger sequencing.  For hybridomas whose productive and 
non-productive rearrangements were not easily separated by gel electrophoresis, the 
DNA was subcloned using a TOPO TA Cloning kit with the pCRII-TOPO vector 
(Invitrogen). 
mAb selection assay 
	
	
34 
 To select for viral escape mutants to selected mAbs, 96 well flat bottom plates 
were coated with 4e4 MDCK cells/well in MEM with 9% FBS and incubated overnight at 
37C.  Virus used in this assay had been serially passaged in eggs a minimum of three 
times to increase mutant frequency.  Virus was incubated with four different 
concentrations of virus to determine a saturating concentration of mAb for one hour at 
room temperature.  MDCK cell-coated plates were washed four times with serum free 
MEM and 100ul of the virus/mAb mixture were transferred to the cells and incubated for 
two hours at 37C.  Plates were subsequently washed and coated with 100ul of MEM 
with 0.1% gentamicin, 1ug/ml TPCK-treated trypsin, and 5 mM HEPES supplemented 
with mAb.  Plates were incubated for three days at 37C.  At this time, cytopathology was 
determined and virus collected from the infection endpoints of those wells that had a 
saturating mAb concentration.  vRNA was collected using a QIAamp viral RNA kit 
(Qiagen) and sequenced to determine the mutation that enabled escape of mAb 
mediated neutralization.  Virus escape mutants collected were subsequently generated 
by reverse genetics, or were subcloned by viral plaque assay.  As a control, cells were 
incubated with virus but without mAb to determine the mutant frequency in the viral 
population. 
Viral plaque assay 
 To subclone virus, 6 well plates (BD) were coated with 5e5 MDCK cells/well in 
MEM with 9% FBS and incubated overnight at 37C. Plates were washed four times with 
MEM and coated with 500ul serially diluted virus in MEM.  Plates were incubated at 37C 
for 1 hour with plates rocked every 15 minutes.  Plates were washed with MEM and 
coated with 1.6% agarose in MEM with 10mM HEPES, 0.1% gentamicin, 1ug/ml TPCK-
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treated trypsin, and 0.05% phenol red.  Three days post infection, isolated plaques were 
collected, confirmed by sequencing, and grown in 10 day old fertilized chicken eggs. 
Statistical analyses 
Student’s t tests, Fisher’s exact tests, area under the curve analyses, standard 
deviation (SD), and standard error of the mean (SEM) were calculated using Graphpad 
Prism6 software (Graphpad Software Inc). 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  PR8 and S12a are antigenically distinct H1N1 viruses. 
(A) PR8 and S12a differ at 13 HA residues (highlighted in black) (Protein database: 
1RVX).  The Sa, Sb, Ca, and Cb antigenic sites are shown in green, purple, blue, and 
red respectively.  (B,C) Mice were immunized i.p. with 1000 HAU PR8 or S12a virus.  
Antigenic 
Site 
Mutations between 
PR8 and S12a 
Sa N129D, K163E 
Sb E156K, G159S 
Ca E70G, K144E, S145N, 
G173R, R224K, D225G 
Cb R48K, R78G, E119K 
A
PR8 S12a
16
32
64
128
256
vaccination
H
AI
 tit
er
HAI titer using PR8 virus
PR8 S12a
16
32
64
128
256
vaccination
H
AI
 tit
er
HAI titer using S12a virusCB
<10 <10
*
*
Figure 1
	
	
37 
Sera were collected 21 days post-vaccination and HAI assays were completed using 
PR8 (B) or S12a (C) virus.  Data are mean +/- SD (*p < 0.0001; Student’s t test). 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  S12a efficiently boosts Abs that react to PR8 HA. 
(A,B) Seven week old BALB/c mice were immunized i.p. with 1000 HAU of PR8 or PBS 
(X) and boosted 28 days later i.v. with 1000 HAU PR8, 1000 HAU S12a, 1000 HAU 
B/Lee, or PBS (X) (n = 4 mice per group). Sera were collected at different times after 
immunization and HAI assays were completed using PR8 (A) and S12a (B) viruses.  
Data are mean +/- SEM.  Mice boosted with both PR8 or S12a had significantly higher 
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PR8 HAI titers compared with mice boosted with PBS (X) or the antigenically unrelated 
B/Lee virus (p < 0.05; Student’s t test).   
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  S12a boosts PR8 Abs at late time points after initial exposure. 
(A) Mice were immunized i.p. with 1000 HAU of PR8 or PBS (X). 70 days later, mice 
were boosted i.v. with 1000 HAU PR8, S12a, J1, or PBS (X). Sera were collected at 
different times after immunization and HAI assays were completed using PR8 virus. 
Mice boosted with PR8 or S12a had significantly higher PR8 HAI titers compared to 
mice boosted with PBS or the unrelated J1 for at least 3 weeks post-boost (p < 0.05; 
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Student’s t test). (B) Mice were immunized i.p. with 1000 HAU PR8 or PBS (X). Mice 
were boosted i.v. with 1000 HAU PR8, S12a, or B/Lee 28 days later. Sera were 
collected 21 days after the boost and tested by ELISA against PR8 virus. Sera from mice 
that were boosted with PR8 or S12a had significantly higher PR8 titers than mice that 
were boosted with negative controls PBS or B/Lee (p < 0.05; Student’s t test of area 
under the curve).  
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Figure 4 
 
 
 
Figure 4.  PR8-S12a sequential exposure elicits many Abs with a classical OAS 
phenotype. 
(A, B) Mice were immunized i.v. with 1000 HAU of PR8 (A) or S12a (B) virus.  
Hybridomas were created from splenocytes collected 5 days after vaccination.  (C, D) 
Mice were immunized i.p. with 1000 HAU of PR8 and boosted i.v 28 days later with 1000 
HAU PR8 (C) or S12a (D).  Hybridomas were produced 3 days after the boost.  We 
completed ELISAs with a range of different mAb concentrations using plates coated with 
PR8, S12a, and J1 (J1 is a virus that has an H3 HA).  mAbs were determined to be PR8 
and/or S12a-specific if they produced an ELISA signal that was 4 times greater using 
PR8 or S12a coated plates compared to plates coated with the J1 negative control.  
Mice boosted with S12a had a higher proportion of Abs cross-reactive for both PR8 and 
S12a (p < 0.005; Fisher’s exact test). 
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Figure 5 
 
 
 
 
 
 
 
Figure 5.  Hybridomas for these experiments were derived from many mice. 
Shown are the fraction of mAbs that were derived from individual mice. (A) 28 mAbs 
were isolated from mice exposed to PR8. (B) 125 mAbs were isolated from mice 
exposed to S12a. (C) 50 mAbs were isolated from mice sequentially exposed to PR8 
twice. (D) 86 mAbs were isolated from mice sequentially exposed to PR8 and S12a. We 
did not use many mice for PR8 primary exposure since previous studies have 
characterized mAbs isolated from mice following a single PR8 exposure.  
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Figure 6 
 
 
 
Figure 6.  Most ‘cross-reactive’ mAbs bind better to PR8 than to S12a.  
(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown 
are 3 mAbs that bound with a higher relative affinity to PR8 than to S12a. As an ELISA 
coating control, we used the stalk-specific C179 mAb that bound with similar affinities to 
both PR8 and S12a (not shown).  
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Figure 7 
 
 
 
 
Figure 7.  ‘OAS’ mAbs bind very poorly to S12a.  
(A-C) mAbs were tested by ELISA for reactivity against PR8, S12a, and J1 virus. Shown 
are three mAbs elicited in mice that received a PR8-S12a prime-boost vaccination that 
had measurable binding to PR8 but not to S12a. As an ELISA coating control, we used 
the stalk-specific C179 mAb that bound with similar affinities to both PR8 and S12a (not 
shown).  
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mAb PR
8
S1
67
Y
K1
65
E
S1
60
L
K1
89
N
N
19
3K
E1
56
K
Q
19
2R
 
S1
40
P 
R
22
4I
 
K1
44
R
L7
5P
 
E1
19
K 
S1
2a
J1
H13 P1 1C
H2 P19C
H5 16B
H5 17B
H5 13A
H5 27B
H5 33D
H9 S2 13A
H4 P38C (IgM)
H5 20B
H5 12A
H2 P4A
H4 P39A (IgM)
H13 P1 7A
H4 P36A
H4 P22C (IgM)
H4 P12C (IgM)
H4 P2A
H5 36B
H13 P2 2B
H9 S2 7D
H13 P2 5B
H13 P1 4D
H2 P3A
H4 P41B
H13 P1 2C
H13 P1 3B
H5 19B
H13 P1 6C
H5 10B
H13 P1 5B
H5 22A
H2 P9A
H13 P2 3B
H5 32C
H5 25B
H9 S2 6C
H4 P31B
H9 S2 4B
H13 P2 6B
H13 P2 4C
H13 P2 1D
H9 S2 3D
H9 S2 1F
H9 S2 11D
H9 S2 5D
H5 34B
H2 P20A
H2 P12C
H13 P1 8A
mAb PR
8
S1
67
Y
K1
65
E
S1
60
L
K1
89
N
N
19
3K
E1
56
K
Q
19
2R
 
S1
40
P 
R
22
4I
 
K1
44
R
L7
5P
 
E1
19
K 
S1
2a
J1
H2 S8B
H13 S2 5D
H5 64B
H5 52A
H5 40B
H5 S17B
H5 55B
H5 53D
H2 S99A
H5 41D
H13 S2 26B
H13 S2 1B
H13 S2 22D
H13 S2 24B
H2 S85C
H2 S80B
H2 S81A
H13 S2 23A
H5 48D
H5 59A
H5 58A
H13 S2 19A
H2 S15B (IgM)
H5 42B
H5 49B
H5 51D
H5 61B
H2 S70B
H2 S31C
H9 S3 1A
H2 S37B
H2 S29A
H13 S1 1C
H13 S1 8A
H13 S1 5B
H13 S1 2B
H13 S1 6A
H5 60A
H13 S1 3C
H13 S1 9C
H5 46A
H2 S95A
H5 50B
H5 57B
H5 74A
H4 S10B
H13 S1 4A
H4 S27B
H4 S32B
H5 44A (IgM)
H5 65A
H5 63A
H5 68B
H2 S48D
H13 S2 25A
H2 S34D
H13 S2 28A
H2 S1A
H4 S37D
H4 S39C
H2 S45A
H2 S36B
H4 S31A
H2 S27B
H2 S92A
H5 67B
H5 45A
H5 70A
H2 S87A
H5 71A (IgM)
H13 S2 29C
H13 S2 2A
H2 S105A
H13 S2 4D
virus virus
A BSa Sb Ca Cb Sa Sb Ca Cb
PR8-PR8 mAbs PR8-S12a mAbs
Figure 4
	
	
47 
Figure 8.  Fine specificity of mAbs elicited by sequential H1N1 exposure. 
(A, B) mAbs created from PR8 pre-exposed mice that were boosted either with PR8 (A) 
or S12a (B) were tested for binding to a panel of viruses by ELISA.  We first completed a 
dose titration of each mAb on ELISA plates coated with PR8.  We determined the lowest 
concentration of each mAb at which PR8 ELISA signal was within 90% of Bmax, and we 
tested this mAb concentration against all of the mutant viruses.  The shade of color in 
each square is relative to the percentage of binding to that virus compared to PR8 
binding with the darkest color being 100% and white being 0%.  The coloring scheme 
(Sa=green, Sb=purple, Ca=blue, Cb=red) matches the coloring scheme of the HA 
structure shown in Figure 1. 
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Figure 9 
 
 
 
 
 
 
 
 
 
Figure 9. The HA Ab response is focused on the Sb antigenic site following 
sequential exposure. 
(A-B) Hybridomas derived from mice that were vaccinated with PR8 virus and boosted 
28 days later with either PR8 (A) or S12a (B) were predominantly specific for the Sb 
antigenic site.  (C-D) This was in contrast to hybridomas derived from mice that were 
immunized only with PR8 (C) or S12a (D) (p < 0.05; Fisher’s exact test).  
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either PR8 (A) or S12a (B) were predominantly specific for the Sb antigenic site.
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A B
expanded Sb mutant panel
mAb PR
8
S1
88
I
L1
94
I
N
18
7H
G
15
9S
I2
17
K
E1
90
K
E1
98
G
Q
19
2R
Q
19
6R
E1
56
K
N
19
3K
K1
89
N
S1
2a
J1
H4 P22C (IgM)
H4 P12C (IgM)
H4 P39A (IgM)
H4 P2A
H4 P31B
H4 P36A
H13 P2 2B
H13 P1 7A
H9 S2 7D
H2 P3A
H4 P41B
H13 P1 4D
H5 36B
H13 P2 3B
H13 P1 2C
H5 10B
H2 P4A
H5 19B
H13 P1 6C
H13 P2 5B
H13 P1 3B
H5 22A
H5 25B
H5 32C
H2 P9A
H13 P1 5B
H5 12A
H9 S2 4B
H5 20B
H4 P38C (IgM)
H9 S2 6C
mAb PR
8
S1
88
I
L1
94
I
N
18
7H
G
15
9S
I2
17
K
E1
90
K
E1
98
G
Q
19
2R
Q
19
6R
E1
56
K
N
19
3K
K1
89
N
S1
2a
J1
H13 S2 23A
H5 58A
H5 59A
H5 48D
H13 S2 19A
H9 S3 1A
H5 46A
H5 57B
H2 S29A
H2 S37B
H5 68B
H5 63A
H2 S48D
H13 S2 28A
H2 S15B (IgM)
H5 42B
H5 49B
H2 S31C
H2 S70B
H5 51D
H5 60A
H5 50B
H5 61B
H4 S27B
H4 S10B
H13 S1 3C
H13 S1 5B
H13 S1 1C
H13 S1 8A
H13 S1 2B
H13 S1 9C
H13 S1 6A
H13 S1 4A
H2 S95A
H5 74A
H5 44A (IgM)
H5 65A
H2 S34D
H13 S2 25A
H13 S2 29C
H4 S32B
expanded Sb mutant panel
PR8-PR8 elicited mAbs PR8-S12a elicited mAbs
C D
156other Sb residues tested
156
other Sb residues tested
S6 Fig. Fine mapping of Sb mAbs reveals that most cross-reactive mAbs are not
sensitive to an E156K HA mutation.
(A, B) mAbs that were derived from mice immunized with PR8 and then boosted 28 days later with
either PR8 (A) or S12a (B) were tested for binding to a panel of viruses.  Twelve of these viruses
had single point mutations at residues in and around the previously defined Sb site.  Most
S12a-reactive mAbs that were elicited by PR8-S12a sequential exposure were resistant to an
E156K HA mutation (highlighted in red).  More E156K-resistant mAbs were derived from PR8-S12a
exposed mice compared to PR8-PR8 exposed mice (highlighted in red).
(C, D) The locations of the point mutations tested in Figure S6A-B are highlighted in green on the
HA structure shown from the side (C) and from the top (D).  Residue 156 is highlighted in red.
	
	
50 
Figure 10.  Fine mapping of Sb mAbs reveals that most cross-reactive mAbs are 
not sensitive to an E156K HA mutation. 
(A, B) mAbs that were derived from mice immunized with PR8 and then boosted 28 days 
later with either PR8 (A) or S12a (B) were tested for binding to a panel of viruses. 
Twelve of these viruses had single point mutations at residues in and around the 
previously defined Sb site. Most S12a-reactive mAbs that were elicited by PR8-S12a 
sequential exposure were resistant to an E156K HA mutation (highlighted in red). More 
E156K-resistant mAbs were derived from PR8-S12a exposed mice compared to PR8-
PR8 exposed mice (highlighted in red).  (C, D) The locations of the point mutations 
tested in Figure S6A-B are highlighted in green on the HA structure shown from the side 
(C) and from the top (D). Residue 156 is highlighted in red.  
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Figure 11 
 
 
 
 
 
 
 
 
Figure 11.  Most Sb mAbs elicited by PR8-S12a sequential exposure are not 
sensitive to the E156K mutations and protect against PR8 and S12a infection. 
(A, B) Sb-specific mAbs from mice pre-exposed to PR8 virus and boosted with either 
PR8 (A) or S12a (B) virus were tested for binding by ELISA to PR8 viruses +/- the 
E156K HA mutation.  mAbs that bound to the E156K mutant >25% relative to PR8 were 
considered ‘E156K-resistant’.  PR8-S12a exposure elicited a higher proportion of 
‘E156K-resistant’ mAbs compared to PR8-PR8 exposure (p < 0.0001; Fisher’s exact 
test).  (C, D) 25ug of the H2-S37B or H4-S10B mAbs were transferred i.p. into mice 12 
hours before infection with 30 TCID50 of PR8 (C) or S12a (D) virus.  Weight loss was 
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measured for 14 days post-infection.  PR8-infected mice that received either mAb lost 
significantly less weight than mice that received a PBS control (no mAb) (p < 0.05 at 
days 3-14 for H2 S37B, p < 0.05 at days 6-14 for H4 S10B; Student’s t test). S12a-
infected mice that received the H4-S10B mAb lost significantly less weight than mice 
that received a PBS control (p < 0.05 at days 7-9; Student’s t test). Data are mean +/- 
SEM. 
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Figure 12 
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Figure 12.  Somatic mutations affect binding to both PR8 and S12a. 
(A-F) Six clonally related (see Table S1) IgG2a mAbs derived from a mouse primed with 
PR8 and boosted with S12a were tested for binding to PR8, S12a, and the antigenically 
unrelated J1 virus via ELISA (J1 is a virus that has an H3 HA).  Data are mean +/- SEM.  
(G)  As an ELISA coating control, the H1 stalk-reactive C179 mAb was tested for binding 
to PR8, S12a, and J1 virus.  Data are mean +/- SEM. 
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Figure 13 
 
 
 
 
 
 
 
 
 
 
Figure 13.  mAbs elicited by PR8-S12a immunization prevent disease caused by 
PR8 and S12a infections. 
(A, B) 25ug of different mAbs were transferred i.p. into mice 12 hours before infection 
with 30 TCID50 PR8 (A) or S12a (B) (n=5 mice per group).  PR8-infected mice that 
received H5-42B, H5-61B, or the PR8 primary mAb lost significantly less weight than 
mice that received a PBS control (no mAb) (p < 0.05 at days 5-14 for H5-42B, p < 0.05 
at days 6-14 for H5-61B, p < 0.05 at days 8-10 for the PR8 primary mAb; Student’s t 
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test). S12a-infected mice that received the H5-42B, H5-61B, or S12a primary mAb lost 
significantly less weight than mice that did not receive mAbs (p < 0.05 at days 8-12 for 
H5-42B, p < 0.05 at days 6-12 for H5-61B, p < 0.05 at days 6-14 for S12a primary mAb; 
Student’s t test). (C) Sera was collected 12 hours after mAb transfer and tested by HAI 
assay against PR8 and S12a virus (n=3 mice per group).  Data are mean +/- SEM. 
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Table 1 
 
Table 1:  Identification of a clonally related family of mAbs.  
Mutations that differ each mAb in the framework regions (FR) or complementarity-
determining regions (CDR) from the heavy chain germline sequence (IGHV5-4*02, 
IGHD2-14*01, IGHJ4*01) are shown using IMGT (International immunogenetics 
information system) numbering (Giudicelli et al., 2011). FR1 was not determined 
because the sequencing primer bound to this region. We also sequenced the CDR3 
region of the light chain (IGKV8-28*01, IGKJ5*01) which was identical between all 6 
mAbs.  
FR2 CDR2
AA residue 29 35 37 38 49 63 66 72 75 84 85 88 92 105 106 108 115
germline ACT AGT TAT TAC AGG AGT TAC AAG CGA AAG AAC TAC AGC GCA AGA GAC ATG
T S Y Y R S Y K R K N Y S A R N M
H5-61B - - - - - - - T - - - - - - A - - - C - - C - - - - - - G - - - - - - - - - - - T - - - G A - T - - -
F H Q R V
H5-42B - - - - - - - - - - - - - - - - - - - - - C - - - - - - G - - - - - T - - - - T - - - - G A - T - - -
Q R F S
H5-49B - - - - - - - - - - - - - - - - - - - - - C - - - - - - G - - - - - - - - - - - T - - - G A - T - - -
Q R V
H5-51D T - - - - - - T - - - - - - - - - - - - T C - - - - - - G - - - - - - - - - - - - - - - G A - T - - -
S F Q R
H5-50B - - - - - C - T - - - T - - A - C - C - - C - - - - C - G - GG - - - - - C - - - - - - G A - - - - -
F T H Q R G T
H5-60A - - - - - C - T - - - - - - A - - - C - - C - - - - - - G - - - - - - - - - - - - - - - G A - - T - -
F H Q R L
CDR1 FR3 CDR3
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CHAPTER 3: POTENTIAL ANTIGENIC EXPLANATION FOR  
ATYPICAL H1N1 INFECTIONS AMONG MIDDLE-AGED ADULTS  
DURING THE 2013-2014 INFLUENZA SEASON 
 
Summary 
Influenza infections usually cause more severe disease in very young or elderly 
individuals.  Intriguingly, H1N1 influenza infections caused an unusually high disease 
burden in middle-aged adults during the 2013-2014 influenza season.  We hypothesize 
that this may be due to increased sensitivity of middle-aged adults to a new mutation 
that had recently been acquired by nearly all contemporary circulating H1N1 strains.  To 
test this hypothesis, we tested sera from healthy human blood donors from different age 
groups against the newly mutated strain.  Interestingly, we found that over 42% of 
individuals born between 1965 and 1979 exhibited reduced binding to the new mutated 
strain compared to the previously circulating strain.  This was in stark contrast to 
younger individuals born between 1985 and 1997 who exhibited no reduction in titers 
against the newly mutated strain.  We also found that mAbs isolated from middle-aged 
adults that bound to this epitope failed to protect mice from infection of the newly 
mutated strain.  We show examples of middle-aged individuals who develop this 
particular specificity after immunization with the previously circulating strain and in 
ferrets sequentially exposed to strains relevant to middle-aged adults.  This suggests 
that while sequential exposure shifts the Ab response to more conserved sites, this may 
ultimately lead to increased susceptibility when viral mutations in these sites occur.  
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Introduction 
In the previous chapter, we have shown in a mouse model that sequential 
exposure to antigenically drifted strains of influenza virus elicits an increased proportion 
of cross-reactive Abs and that the specificity of mAbs shifts towards more conserved 
epitopes that are less sensitive to mutations that differ between the strains.  Surprisingly, 
we also found that even OAS Abs that bind with a higher affinity to the priming strain can 
provide modest protection against influenza infections and may be precursors to more 
cross-reactive Abs though somatic hypermutation.  
Unfortunately, influenza viruses are constantly mutating, and humans are 
potentially exposed to antigenically drifted viral strains on an annual basis.  Shifts in 
epitope immunodominance have been shown to occur due to pre-exposure history (Li et 
al., 2013).  As individuals from different age groups have different pre-exposure histories 
due to the persistent change in circulating viral populations, we hypothesize that this 
may explain why different age groups have different influenza virus-specific Ab 
repertoires.  This suggests that while OAS Abs can have positive protective qualities due 
to limited cross-reactivity between two strains, the gradual shift of the Ab response to 
momentarily conserved epitopes may also lead to increased susceptibility should a virus 
arise that has mutations that abrogate Ab binding to a previously conserved region. 
Results 
An HA mutation acquired prior to the 2013-2014 influenza season is antigenically 
relevant in middle-aged adults 
While the H1N1 component of the vaccine was not updated for the 2013-2014 
season, mutations have been accumulating in circulating pH1N1 strains since the virus 
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arose in 2009 (Figure 14C).  A K166Q mutation located on the distal head of the HA that 
was first sequenced from viral isolates in the 2012-2013 season became rapidly fixed in 
the circulating viral population (Figure 14A-B).  This mutation has previously been 
considered antigenically neutral based on experiments using primary antisera from 
ferrets infected with the 2009 pH1N1 strain (Arriola, 2014).  However, the antigenicity of 
this region may have been underrepresented by these experiments as primary antisera 
to the pH1N1 strain have been shown to be focused to other regions of the HA, 
particularly those epitopes containing residues 156, 157, and 158 (Chen et al., 2010; Li 
et al., 2013).  The amino acids at residues 156, 157, and 158 have not been extensively 
mutated in pH1N1 strains circulating between 2009 and 2014 (Figure 15).  In contrast to 
the ferrets used in surveillance experiments, humans are sequentially exposed to 
antigenically drifted strains throughout their lives.  To test whether human sera binds to 
this newly mutated epitope, we tested sera collected from healthy human blood donors 
during the 2013-2014 influenza season by HAI against the wild type (WT) pH1N1 strain, 
and a pH1N1 strain engineered to contain the newly acquired K166Q mutation.  
Interestingly, we found that 27% of sera from individuals born between 1940 and 1984 
had at least a twofold reduction in titers to the new mutant virus when compared to the 
WT strain.  Remarkably, over 42% of individuals born from 1965 to 1979 (n = 54 
individuals) also demonstrated this reduction.  This is in contrast to younger individuals 
born from 1985 to 1997 (n = 49 individuals) who did not have a measurable decrease in 
serum titers to the newly mutated strain (Figure 16A, Table 2). This difference in K166 
specificity between these two age groups was statistically significant (p < 0.0001; 
Fisher’s exact test).  Similar results were obtained when we tested sera from healthy 
human adults collected during the 2013-2014 influenza season in Mexico (Figure 17, 
Table 3). 
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The difference in K166 epitope immunodominance is due to unique pre-exposure history 
We hypothesize that the difference between these two age groups is due to a 
difference in pre-exposure history.  We propose that the Abs elicited in middle-aged 
adults that are specific for this newly mutated epitope were elicited by previously 
circulating sH1N1 strains circulating in humans before 1985 and then recalled by the 
2009 pH1N1 strain.  sH1N1 strains that circulated in the late 1970s and early 1980s 
share extensive homology with the pH1N1 strain (Figure 16B) and H1N1 strains did not 
circulate in humans from 1957 to 1976, so adults born after 1957 would have been 
potentially exposed to H1N1 strains as early as 1977.  In contrast, sH1N1 strains 
acquired a mutation that introduced a glycosylation site at HA residue 129.  This 
glycosylation site blocks binding of K166-specific mAbs (Linderman et al., 2014).  We 
hypothesize that K166 epitope specific Abs were not elicited by seasonal strains 
circulating after 1985 when the glycosylation site that shields this epitope was introduced 
and so were not recalled by infection or immunization with the pH1N1 strain that lacks 
this glycosylation.  To test our hypothesis that sequential exposure to strains circulating 
before 1985 and the 2009 pH1N1 strain affected the prevalence of K166-specific Abs, 
we tested sera from humans born before 1984 that was collected before and after 
vaccination with the 2009 pH1N1 strain.  As these sera were collected in 2009, most 
individuals did not have measurable titers to the 2009 pH1N1 strain before vaccination.  
Sera from 5 out of 17 individuals demonstrated a measurable increase in K166 epitope 
specific titers after vaccination with the 2009 pH1N1 (Figure 18A, Table 4).  We also 
measured binding of 42 head specific mAbs collected from 12 adult donors (born 1949-
1985) that were vaccinated with the pH1N1 strain in 2009.  Remarkably, 23% of these 
mAbs had reduced binding to a pH1N1 K166Q mutant virus compared to the WT 2009 
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pH1N1 strain (Figure 18B). We hypothesize that these Abs were previously elicited by 
seasonal strains and recalled by the 2009 pH1N1 vaccination.  To test this in a more 
controlled animal model, we sequentially infected ferrets with sH1N1 strains that 
circulated in 1977, 1983, or 1986, followed by infection with the 2009 pH1N1 strain.  As 
controls, we infected previously naïve ferrets with the 2009 pH1N1 strain and also 
sequentially infected ferrets with the 2009 pH1N1 strain twice.  Three out of eight ferrets 
that were infected with the pH1N1 strain after pre-exposure to the A/Chile/01/1983 virus 
had detectable K166 specific titers (Figure 19, Table 5).  This was in contrast to ferrets 
pre-exposed to the A/Singapore/06/1986 strain which has a glycosylation site that is 
predicted to shield the region around residue 166, as well as ferrets pre-exposed to the 
A/USSR/90/1977 strain.  The A/USSR/90/1977 - A/California/07/2009 strain likely did not 
recall K166 HA specific mAbs because of variation at residue 125, which is in close 
proximity to residue 166 (Figure 20).  Neither ferrets that received one pH1N1 infection 
or two sequential pH1N1 infections elicited detectable K166 HA specific titers.    
K166 HA-specific Abs are less effective against K166Q HA mutant virus infection 
In the previous chapter, we showed that even Abs with low affinity for a mutated 
strain could protect against infection.  We passively transferred a K166 HA specific mAb 
(SFV009—3F05) or a control mAb that binds equally well to the K166Q HA mutant and 
WT strains (SFV015-1F02) to BALB/c mice 12 hours prior to infection with the WT 
pH1N1 strain or a K166Q HA mutant strain (Figure 18C).  While both mAbs protected 
against the WT pH1N1 strain, the K166 HA specific mAb failed to protect mice against 
infection with the K166Q HA mutant strain.  In addition, we tested human sera by in vitro 
neutralization assay.  Sera that had K166 HA specificity based on HAI assays failed to 
efficiently neutralize K166Q HA mutant viruses (Table 6).  This suggests that K166 HA 
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specific Abs can be less effective at preventing disease.  As we have shown that these 
types of mAbs are more common in middle-aged adults, this offers a potential antigenic 
explanation for the increased disease burden in middle-aged adults that occurred during 
the 2013-2014 influenza season.   
Discussion 
Our studies suggest that an HA mutation that was first recognized during the 
2012-2013 influenza season is antigenically relevant and potentially physiologically 
relevant in a subset of the population.  The antigenic change caused by the K166Q HA 
mutation may have been previously overlooked as primary ferret sera to the pH1N1 
strain do not represent the influenza-specific Ab repertoire in humans who are exposed 
to influenza viruses repeatedly throughout life.  To complicate matters, since influenza 
viruses are constantly mutating, individuals from different age groups have unique pre-
exposure histories.  We hypothesize that this affects the influenza-specific Ab repertoire 
and may explain the unusually high level of disease in middle-aged adults during the 
2013-2014 influenza season.  We have shown here that the K166Q HA mutation 
abrogates binding of Abs prevalent in middle-aged adults.  Previous studies have shown 
that sequentially infecting ferrets with antigenically drifted strains of influenza shifts the 
influenza-specific Ab response to focus on different epitopes (Li et al., 2013).  We have 
recapitulated this and found that some ferrets pre-exposed to a previously circulating 
seasonal strain elicit a strong Ab response against this newly mutated region of the HA.  
In addition, we have found that vaccination with the pH1N1 strain can increase the titers 
of Abs of this specificity.  These Abs have reduced neutralization capabilities against the 
newly mutated strain.  This suggests that surveillance of influenza viruses should take 
into account the effect of pre-exposure history on the influenza-specific Ab repertoire 
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when considering whether a new mutation that arises in the circulating viral population 
constitutes an antigenic change. In addition, these studies suggest that pre-exposure 
history not only affects the Ab repertoire, but may also affect susceptibility to influenza 
infection.  
Materials and Methods       
Human Donors  
Studies involving human adults were approved by the Institutional Review 
Boards of Emory University, Vaccine and Gene Therapy Institute of Florida, the National 
Institute of Respiratory Diseases of Mexico, and the Wistar Institute. Informed consent 
was obtained. For all experiments, HAI and in vitro neutralization assays were 
completed at the Wistar Institute using preexisting and de-identified sera. We analyzed 
several serum panels in this study. We analyzed sera from healthy donors collected at 
the New York Blood Center in February of 2014. We analyzed sera from healthy donors 
collected at the Center for Research in Infectious Diseases at the National Institute of 
Respiratory Diseases in Mexico. We analyzed sera and mAbs derived from healthy 
donors vaccinated with a monovalent pH1N1 vaccine in 2009 as previously described (Li 
et al., 2012). 
Viruses 
Viruses possessing WT pH1N1 HA or K166Q pH1N1 HA were generated via 
reverse-genetics using HA and NA genes from A/California/07/2009 and internal genes 
from A/Puerto Rico/08/1934. All of these viruses were engineered to possess the 
antigenically neutral D225G HA mutation, which facilitates viral growth in fertilized 
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chicken eggs (Chen et al., 2010).  Viruses were grown in fertilized chicken eggs and the 
HA genes of each virus stock were sequenced to verify that additional mutations did not 
arise during propagation. sH1N1 strains (A/USSR/90/1977, A/Chile/01/1983, 
A/Singapore/06/ 1986, A/Texas/36/1991, A/New Caledonia/20/1999, and A/Solomon 
Islands/03/2006) were also grown in fertilized chicken eggs. We isolated a pH1N1 virus 
from respiratory secretions obtained from a patient from the Children’s Hospital of 
Philadelphia in 2013 (A/CHOP/1/13). For this process, de-identified clinical material from 
the Children’s Hospital of Philadelphia Clinical Virology Laboratory was added to MDCK 
cells (originally obtained from the National Institutes of Health) in serum-free media with 
TPCK-treated trypsin (Worthington), HEPES (Cellgro), and gentamicin (Gibco). Virus 
was isolated from the MDCK-infected cells 3 days later. We extracted viral RNA and 
sequenced the HA gene of A/CHOP/1/13.  
Animal Experiments 
Murine experiments were performed at the Wistar Institute according to protocols 
approved by the Wistar Institute Institutional Animal Care and Use Committee. BALB/c 
mice (Charles River Laboratories) were injected with 25 µg of mAb i.p. and then infected 
intranasaly with 20,000 TCID50 of WT or K166Q-HA pH1N1 virus 12 hours later. As 
controls, some mice received an i.p injection of PBS (Cellgro) before infection. Weight 
loss and survival was recorded for 11 days. Severely sick mice were euthanized. Ferret 
experiments were performed at the Vaccine and Gene Therapy Institute of Florida in 
accordance with the National Research Council’s Guide for the Care and Use of 
Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in 
Microbiological and Biomedical Laboratories handbook (Council, 2011).  Fitch ferrets 
(Marshall Farms) were infected with 1 × 106 PFU of sH1N1 virus and bled 14 and 84 
	
	
66 
days later. These ferrets were then infected with the A/California/ 07/2009 pH1N1 strain 
and bled 14 days later. Some ferrets were sequentially infected with 
A/California/07/2009 (84 days between infections) and other ferrets were infected with 
only A/California/07/2009 and bled 14 days later. 
HAI Assays 
Sera samples were pretreated with receptor-destroying enzyme (Key Scientific 
Products or Sigma-Aldrich) and HAI titrations were performed in 96-well round bottom 
plates (BD). Sera were serially diluted twofold and added to four agglutinating doses of 
virus in a total volume of 100 µL. Turkey erythrocytes (Lampire) were added [12.5 µL of 
a 2% (vol/vol) solution]. The erythrocytes were gently mixed with sera and virus and 
agglutination was read out after incubating for 60 minutes at room temperature. HAI 
titers were expressed as the inverse of the highest dilution that inhibited four 
agglutinating doses of turkey erythrocytes. Each HAI assay was performed 
independently on three different dates. Sera that had at least twofold reduced HAI titers 
using K166Q HA mutant viruses in three independent HAI assays were labeled as “K166 
HA-specific.” 
ELISA 
Viruses for ELISAs were concentrated by centrifugation at 20,000 RPM for 1 
hour using a Thermo Scientific Sorvall WX Ultra 80 Centrifuge with a Beckman SW28 
rotor. Concentrated viruses were then inactivated by BPL (Sigma-aldrich) treatment. 
Viruses were incubated with 0.1% BPL and 0.1M HEPES overnight at 4C followed by a 
90 minute incubation at 37 °C. The 96-well Immulon 4HBX flat-bottom microtiter plates 
(Fisher Scientific) were coated with 20 HAU per well BPL-treated virus overnight at 4 °C. 
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Each human mAb was serially diluted in PBS and added to the ELISA plates and 
allowed to incubate for 2 hours at room temperature. As a control, we added the 70-
1C04 stalk-specific mAb to verify equal coating of WT and K166Q HA virus. Next, 
peroxidase conjugated goat anti-human IgG (Jackson Immunoresearch) was incubated 
for 1 hour at room temperature. Finally, Sureblue TMB Peroxidase Substrate (KPL) was 
added to each well and the re-action was stopped with addition of 250 mM HCl solution. 
Plates were extensively washed with water between each ELISA step. Affinities were 
determined by nonlinear regression analysis of curves of 6 mAb dilutions (18 µg/mL to 
74 ng/mL) using Graphpad Prism. mAbs were designated as K166 specific if they had a 
Kd at least four times greater for the K166Q mutant than for the WT virus. 
In Vitro Neutralization Assay 
Sera were serially diluted and then added to 100 TCID50 units of virus and 
incubated at room temperature for 30 minutes. The virus-serum mixtures were then 
incubated with MDCK cells for 1 hour at 37 °C. Cells were washed and then serum-free 
media with TPCK-treated trypsin was added. Endpoints were determined visually 3 days 
later. Data are expressed as the inverse of the highest dilution that caused 
neutralization. All samples were repeated in quadruplicate and geometric mean titer is 
reported. 
Structural Modeling of HA Glycosylation Sites  
Glycans were modeled onto positions 129 and 131 in the A/Solomon 
Islands/03/2006 HA crystal structure (PDB ID code 3SM5) using the GLYCAM Web 
Glycoprotein Builder (www.glycam.org). The particular glycan used for modeling was an 
N-linked glycan with a trimannosyl core (DManpa1-6[DGlcpNAcb1-2DManpa1-
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3]DManpb1-4DGlcpNAcb1- 4DGlcpNAcb1-OH in Glycam notation), and default rotamer 
settings were used for modeling. To model the 131 glycosylation site, a T131N mutation 
was introduced using the PyMol structure viewer before the structure was uploaded to 
the GLYCAM-Web server.  
Computational and Phylogenetic Analyses of HA Sequences  
The occurrence of different amino acid identities at HA residues 166, 156, 157, 
and 158 (H3 numbering) was analyzed by downloading all full-length human pandemic 
H1N1 sequences present in the Influenza Virus Resource as of February 23, 2014 (Bao 
et al., 2008).  After purging sequences that were less than full length, contained 
ambiguous nucleotide identities, lacked full (year, month, day) isolation dates, or were 
otherwise anomalous, the sequences were aligned. Each calendar year was broken into 
four equal partitions beginning with January 1, and the frequencies of different amino 
acids at each residue of interest for each partition was calculated and plotted. Only 
amino acids that reached a frequency of at least 1% in at least one of the year partitions 
are labeled in the legend to the plot. For construction of phylogenetic trees, the 
sequence set was randomly subsampled to 10 sequences per quarter-year partition. 
BEAST was then used to sample from the posterior distribution of phylogenetic trees 
with reconstructed sequences at the nodes, after date stamping the sequences, using a 
JTT with a single rate category with an exponential prior, a strict molecular clock, and 
relatively uninformative coalescent-based prior over the tree (Drummond et al., 2012; 
Jones et al., 1992).  Fig. 1C shows a maximum clade credibility summary of the 
posterior distribution with branches colored according to the reconstructed amino acid 
identity at site 166 with the highest posterior probability at their descendent nodes. The 
tree was visually rendered using FigTree. The input data and computer code used for 
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this analysis can be found on GitHub at github.com/jbloom/pdmH1N1_ 
HA_K166_mutations.  
Statistical Analyses  
For all serum experiments, we excluded samples that did not have positive 
pH1N1 HAI titers. All samples that were pH1N1 HA-WT HAI negative were also pH1N1 
HA-K166Q HAI-negative. Samples were allocated to specific groups based on age of 
donor. The year of birth of each sample was available during the experiment, but this 
information was not assessed until each experiment was completed. Variance of raw 
HAI titers was similar between different age groups. Fisher’s exact tests were completed 
using SAS v9.3 software. 
 
 
 
 
 
 
 
 
 
	
	
70 
Figures and Tables 
Figure 14 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  pH1N1 viruses rapidly acquired HA mutation K166Q during the 2013–
2014 influenza season.  
(A) Residue K166 (red) is shown on the A/California/04/2009 HA trimer [PDB ID code 
3UBN (Xu et al., 2010)]. (B) Plotted is the frequency of different amino acid identities at 
HA residue 166 in pH1N1 HA sequences as a function of time. Nearly all pH1N1 
possessed K166 from 2009 to mid-2012, but most isolates possessed Q166 by the 
2013–2014 season. (C) A phylogenetic tree of pH1N1 viruses with branches colored 
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according to amino acid identity at site 166 illustrates the rapid fixation of K166Q in 
recent pH1N1 isolates. 
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Figure 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Sequence variation of pH1N1 HA.  
The residues in the dominant antigenic site recognized by primary ferret anti-sera 
(residues 156, 157, and 158 of the Sa antigenic site) are highly conserved in pH1N1 (A–
C). No variation greater than 1% occurred at residue 156 and very little variation 
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occurred at residues 157 and 158. For comparison, residue 166 (D; also shown in Fig. 
1B) has undergone a complete change in the last year.  
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Figure 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Adult humans possess Abs that bind to a region of HA that was 
recently mutated in pH1N1.                
(A) Sera were isolated from healthy donors (n = 195) from the state of New York during 
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the 2013–2014 influenza season. HAI assays were performed using viruses with either 
WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For 
each sera sample, we completed three independent HAI assays. Raw HAI data are 
reported in Table 2. Percentages of samples that had at least a twofold reduction in HAI 
titer using the mutant virus in three independent experiments are shown. K166 specificity 
of sera from individuals born between 1965 and 1979 is statistically significant compared 
with K166 specificity of sera from individuals born after 1985 (*p < 0.0001; Fisher’s exact 
test). (B) Homology between the A/Chile/01/1983 sH1 and the A/California/04/2009 pH1 
are shown using the crystal structure of the A/California/04/2009 HA [PDB ID code 
3UBN (Xu et al., 2010)]. Residue K166 is colored green. Amino acids that differ between 
A/Chile/01/ 1983 and A/California/04/2009 are shown in red. The glycan receptor is 
shown in black. 
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Figure 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Mexican donors born before 1985 possess Abs that bind to the region 
of HA that was recently mutated in pH1N1.                                                                  
Sera were isolated from healthy donors (n = 45) at the Center for Research in Infectious 
Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–
2014 influenza season. HAI assays were performed using viruses with either WT 
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For 
each sera sample, we completed three independent HAI assays. Raw HAI data are 
reported in Table 3. Percentages of samples that had at least a twofold reduction in HAI 
titer using the mutant virus in three independent experiments are shown. (*p < 0.05; 
Fisher’s exact test).  
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Figure 18 
 
 
 
 
 
 
 
Figure 18.  Vaccination of middle-aged adults with the current pH1N1 vaccine 
strain elicits Abs that bind to a region of HA that is now mutated in most pH1N1 
isolates. 
 (A) Healthy adult volunteers were vaccinated with a monovalent pH1N1 vaccine in 
2009. Sera were isolated pre-vaccination and 30 days post-vaccination and HAI assays 
were performed using viruses with either WT A/California/07/2009 HA or 
A/California/07/2009 HA with a K166Q HA mutation. Shown are HAI titers for donors that 
possessed K166 HA-specific Abs following vaccination. Data are representative of three 
independent experiments. Raw HAI titers for all donors are shown in Table 4. (B) 
ELISAs were completed using mAbs isolated from healthy adult volunteers that were 
vaccinated with a monovalent pH1N1 vaccine in 2009. ELISAs were coated either with 
A/California/07/2009 (WT) or A/California/07/2009 with a K166Q HA mutation. Shown 
are percentage of mAbs that bound to both viruses and percentage of mAbs that bound 
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to the WT virus but not the mutant virus (n = 42 mAbs). Data are representative of two 
independent experiments. (C) A K166 HA specific mAb (SFV009-3F05) or a mAb that 
recognizes both WT and K166Q HA pH1N1 (SFV015-1F02) were injected into BALB/c 
mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000 TCID50 
of WT or K166Q HA virus and weight loss and survival were recorded for 11 days. Data 
are representative of two independent experiments. 
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Figure 19  
 
 
 
 
 
 
 
 
Figure 19.  Ferrets sequentially infected with A/Chile/01/1983 and A/California/ 
07/2009 develop K166 HA specific Abs.  
Ferrets were infected with a sH1N1 virus and then reinfected 84 days later with the 
A/California/07/2009 pH1N1 virus. Sera were collected 14 days after the second 
infection and HAI assays were completed using WT and K166Q-HA pH1N1 viruses. 
Shown are percentages of samples that had at least a twofold reduction in HAI titer 
using the K166Q HA mutant virus in three independent experiments. Raw HAI titers are 
shown in Table 5. The difference in K166 HA specificity is statistically significant 
comparing the A/Chile/01/1983-A/California/07/2009 group with the rest of the groups (3 
of 8 vs. 0 of 22; p < 0.05; Fisher’s exact test). 
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Figure 20 
 
Figure 20.  Homology between A/USSR/90/1977, A/Chile/01/1983, and 
A/California/07/2009.  
HA residues that differ between A/Chile/01/1983 and the A/California/ 07/2009 are 
shown in red. A few additional HA residues differ between the HAs of A/USSR/90/1977 
and A/California/7/2009, and these are colored yellow. Of note, A/Chile/01/1983 and 
A/California/07/2009 both possess S125 whereas A/USSR/90/1977 possess R125. 
Residues 125 and 166 are next to each other in the structure. PDB ID file 3UBN 
(A/California/04/2009 HA) was used to make this figure.  
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Table 2 
 
experiment #1 experiment #2 experiment #3 
  
HAI titers HAI titers HAI titers 
sample ID YOB WT K166Q WT K166Q WT K166Q 
40-60 1940 160 80 160 80 160 60 
40-49 1943 80 <20 60 <20 80 <20 
40-05 1948 160 80 160 80 160 80 
40-02 1948 120 60 60 30 80 30 
40-44 1948 320 80 320 80 320 80 
40-14 1949 240 80 240 80 240 80 
40-16 1949 240 <20 160 <20 160 <20 
50-55 1952 160 80 160 60 160 80 
50-11 1952 120 40 80 30 80 30 
50-43 1953 80 40 80 40 80 40 
50-06 1959 120 60 80 40 80 30 
60-04 1963 80 40 80 40 80 40 
60-10 1963 160 80 240 80 160 60 
60-13 1964 240 120 320 120 240 120 
60-25 1964 60 20 80 30 60 20 
60-14 1967 160 80 120 60 120 60 
60-23 1967 320 120 320 160 320 160 
60-44 1968 160 80 160 80 160 80 
60-28 1969 320 160 320 160 320 160 
60-41 1969 120 60 160 80 160 80 
60-63 1969 120 60 120 60 120 60 
60-35 1969 80 40 80 30 80 30 
70-56 1971 80 40 80 30 80 40 
70-52 1971 160 <20 120 <20 80 <20 
70-60 1972 160 80 160 80 160 80 
70-74 1972 160 80 240 80 240 80 
70-36 1972 240 60 240 30 320 30 
70-84 1973 120 40 160 30 160 40 
70-86 1973 160 40 160 30 160 40 
70-13 1975 640 320 640 320 640 320 
70-54 1975 160 80 80 30 120 60 
70-25 1975 160 80 80 30 120 40 
70-10 1975 160 30 80 30 80 30 
70-23 1975 160 <20 120 <20 160 <20 
70-82 1976 160 80 160 60 160 80 
70-50 1976 240 80 160 60 120 60 
70-80 1978 320 160 320 160 320 160 
70-19 1978 80 <20 80 <20 80 <20 
80-16 1980 80 30 60 20 80 40 
80-48 1983 640 120 640 80 640 80 
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Table 2:  HAI titers using sera from healthy donors from the United States.   
Sera were isolated from 195 healthy donors from the state of New York during the 2013-
2014 influenza season.  HAI assays were performed using viruses with either wild-type 
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation.  For 
each serum sample, we completed 3 independent HAI assays.  Shown are samples that 
had at least a twofold reduction in HAI titer using the mutant virus in 3 independent 
experiments.   
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Table 3 
 
 
 
 
 
 
 
 
 
 
Table 3:  HAI titers using sera from healthy donors from Mexico.   
Sera were isolated from 45 healthy donors from Mexico during the 2013-2014 influenza 
season.  HAI assays were performed using viruses with either wild-type 
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation.  For 
each serum sample, we completed 3 independent HAI assays.  Shown are samples that 
had at least a 2-fold reduction in HAI titer using the mutant virus in 3 independent 
experiments.   
 
 
 
 
 
 
  
 experiment #1    experiment #2    experiment #3 
  
   HAI titers    HAI titers    HAI titers 
sample ID YOB WT K166Q WT K166Q WT K166Q 
N-33 1973 160 60 120 40 80 30 
N-42 1975 40 <10 30 <10 30 <10 
N-93 1977 120 30 60 30 60 20 
N-72 1979 30 <10 30 <10 20 <10 
N-70 1980 160 80 120 60 120 40 
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Table 4 
K166-specific donors 
         
 
visit 1  
(pre-vaccine) 
 
visit 2  
(post-vaccine) 
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 1 1979 240 160 320 60 80 120 20 
 
160 20 
 6 1966 160 120 240 120 240 <10 <10 
 
40 10 
 7 1966 40 60 30 10 60 <10 <10 
 
120 <10 
 13 1982 80 40 80 40 60 10 <10 
 
160 10 
 21 1958 60 30 80 40 80 <10 <10 
 
60 20 
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 2 1976 80 80 120 <10 <10 60 60 
 
80 60 
 5 1949 10 <10 <10 10 40 10 <10 
 
40 40 
 8 1961 40 <10 30 80 120 <10 <10 
 
80 80 
 9 1977 80 80 80 <10 <10 <10 <10 
 
120 80 
 10 1983 80 <10 320 240 320 <10 <10 
 
240 320 
 15 1961 <10 <10 <10 <10 <10 <10 <10 
 
80 80 
 17 1956 40 <10 30 80 120 10 <10 
 
20 20 
 19 1961 80 40 160 80 80 <10 <10 
 
20 20 
 20 1945 40 <10 <10 <10 <10 <10 <10 
 
240 320 
 22 1956 30 30 60 <10 <10 <10 <10 
 
240 240 
 23 1975 40 <10 240 80 120 <10 <10 
 
160 160 
 24 1968 <10 <10 30 <10 <10 <10 <10 
 
60 60 
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Table 4:  Vaccination elicits K166 HA specific responses.   
HAI assays were completed using sera isolated from healthy donors before and after 
vaccination with the monovalent pH1N1 virus in 2009.  Post-vaccination sera were 
collected 30 days after vaccination.  HAI assays using post-vaccine sera were 
completed 3 independent times and assays using pre-vaccine sera were completed 2 
independent times. 
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Table 5 
 
First second 
 
day 14 day 84 day 98 
Infection infection animal WT K166Q WT K166Q WT K166Q 
A/USSR/90/77 A/CA/07/09 7982 <10 <10 <10 <10 800 800 
  7983 <10 <10 <10 <10 800 800 
  7984 <10 <10 <10 <10 300 300 
  7985 <10 <10 <10 <10 800 600 
  7991 <10 <10 <10 <10 2400 2400 
  7993 <10 <10 <10 <10 800 1200 
  7994 <10 <10 <10 <10 600 600 
  7995 <10 <10 <10 <10 400 600 
A/Chile/01/83 A/CA/07/09 7987 <10 <10 <10 <10 1200 800 
  7988 <10 <10 <10 <10 800 400 
  7989 <10 <10 <10 <10 800 400 
  7990 <10 <10 <10 <10 1600 1600 
  7996 <10 <10 <10 <10 1200 400 
  7997 <10 <10 <10 <10 240 160 
  8000 <10 <10 <10 <10 600 800 
  8001 <10 <10 <10 <10 800 800 
A/SI/06/86 A/CA/07/09 1487 <10 <10 80 120 6400 6400 
  1488 <10 <10 <10 <10 3200 3200 
  1481 <10 <10 <10 <10 2400 3200 
  1504 <10 <10 60 80 4800 6400 
  8002 <10 <10 <10 <10 1600 2400 
  8009 <10 <10 <10 <10 1600 2400 
  8010 <10 <10 <10 <10 4800 6400 
  8012 <10 <10 <10 <10 1600 2400 
A/CA/07/09 A/CA/07/09 8013 400 400 200 200 160 160 
  8014 800 800 400 400 2400 2400 
  8015 800 800 300 200 2400 1600 
None A/CA/07/09 1486 1600 2400 ND ND ND ND 
  1497 1600 1600 ND ND ND ND 
  1492 1200 1600 ND ND ND ND 
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Table 5:  Sequential infection in ferrets can elicit K166 HA specific Abs.   
Ferrets were infected with a sH1N1 virus and bled 14 and 84 days later. Animals were 
then infected with a pH1N1 strain and bled 14 days later (98 days post first infection). 
Sera were isolated and HAI assays were completed using WT and K166Q HA pH1N1 
viruses. Data are representative of three independent HAI assays. The three ferrets with 
K166 HA specific Ab responses had >twofold changes in HAI titer using the K166Q virus 
in three independent experiments. Red highlights twofold or greater reductions in HAI 
titer using K166Q HA pH1N1 virus compared to WT HA pH1N1 virus. ND, not 
determined.  
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Table 6 
     
in vitro 
 
  
HAI titers neutralization titers 
sample 
# YOB A
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 40-49 1943 20 <10   24 12 
 40-44 1948 160 30   453 95 
 40-16 1949 80 <10   160 20 
 70-52 1971 40 <10   190 28 
 70-36 1972 120 10   381 95 
 70-84 1973 40 <10   160 57 
 70-86 1973 60 20   190 67 
 70-23 1975 80 <10   226 20 
 70-19 1978 30 <10   95 10 
 80-48 1983 320 30   1076 80 
 80-10 1986 160 160   761 1810 
 80-26 1986 80 80   113 160 
 80-74 1986 40 40   135 113 
 80-30 1987 20 10   67 113 
 80-34 1987 160 160   381 538 
 80-56 1988 20 <10   17 34 
 90-01 1990 40 10   48 80 
 90-24 1991 60 20   34 95 
 90-12 1992 160 60   190 226 
 90-13 1992 80 80   190 320 
 
Table 6: Characterization of K166 HA-specific sera.   
We further characterized several serum samples that had immunodominant K166 HA 
specific Abs (light grey = K166 HA specific sera from individuals born prior to 1985; 
darker grey = sera from individuals born after 1985).  HAI assays were completed using 
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viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated from 
the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization 
assays were completed using the reverse-genetics derived viruses.  Data are 
representative of 2 independent experiments. For each neutralization assay, each 
sample was titered 4 times, and geometric mean of these quadruplicate samples is 
reported.   
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CHAPTER 4:  CONCLUDING REMARKS  
AND FUTURE DIRECTIONS 
 
It has long been held that exposure to an antigen leads to an anamnestic 
response that can provide protection.  Thucydides recorded that in the second year of 
the Peloponnesian war (430 BCE) Athens suffered from a terrible plague, and that the 
sick found the most help from those who had recovered from the disease as these “had 
now no fear for themselves; for the same man was never attacked twice - never at least 
fatally. And such persons not only received the congratulations of others, but themselves 
also, in the elation of the moment, half entertained the vain hope that they were for the 
future safe from any disease whatsoever” (Thucydides, 431 BCE).  This observation of 
protection has lead to the development of vaccines, most of which are thought to 
function by inducing a protective Ab response as well as eliciting memory B cells that are 
poised to respond rapidly to a secondary exposure.  However, when the antigen used to 
recall a previously primed response differs from the original priming antigen as is the 
case with rapidly mutating viruses such as influenza virus or HIV, this complicates the 
recall response.   
Shifting the antibody response 
Early influenza studies suggest that recalling previously elicited influenza specific 
B cells that have only a low affinity for the new, mutated strain may be detrimental to the 
development of a higher affinity de novo response to the more recent strain.  However, it 
has also been found that while de novo Ab responses specific for the secondary strain 
may be lower in individuals who have been pre-exposed to an antigenically different 
strain, the viral titers themselves are also lower in these pre-exposed individuals, 
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suggesting that additional protection and thereby a lower dose of antigen may be 
responsible for the reduction in de novo Ab titers (Kim et al., 2009).  
Additional work has also shown that previous exposure can affect the Ab 
repertoire by shifting the focus of the Ab response to epitopes that are conserved 
between two sequentially infecting strains (Li et al., 2013; Wrammert et al., 2011).  This 
is thought to be due to MBC clones responding more efficiently and therefore 
outcompeting naïve B cell clones that are specific for newly formed epitopes (Hebeis et 
al., 2004; Liu et al., 1995; Martin and Goodnow, 2002; Tangye et al., 2003).  
Interestingly, we found that the majority of the mAbs that we produced in PR8 pre-
exposed mice were specific for the Sb and Sa sites on the distal head of the influenza 
HA in both the mice boosted with the PR8 strain or the antigenically distinct S12a strain.  
This suggests that shifting immunodominance hierarchies may require more extensive or 
precise alteration of the Ab footprint or additional exposures, as the antigenically drifted 
strain could recall previously elicited clones of relatively low affinity.  Shifting Ab 
immunodominance to highly conserved sites is the target of several experimental 
vaccine regimens designed to broaden and increase protection against rapidly mutating 
and diverse viral populations (Ellebedy et al., 2014; Krammer et al., 2013; Wei et al., 
2010).  Thus we see that our goals have not changed much from the time of the 
Peloponnesian war when many hoped their past infection would protect them from a 
broader array of disease.  Understanding how Ab specificity changes after a secondary 
response to an altered antigen will help us better understand not only how these 
changes may affect protection, but also inform future vaccine design.   
Here we observe how Ab fine specificity changes early in the secondary 
response to an antigenically drifted virus with a heavily mutated HA molecule.  We found 
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that exposure to a drifted strain increased the proportion of Abs that were cross-reactive 
between the two strains, but rather than focusing the Ab response on highly conserved 
epitopes in the stalk or head region of the HA, vaccination with the antigenically drifted 
S12a strain recalled Ab specificities that had slightly altered footprints in the variable 
regions of the HA head.  This is in contrast to other published studies that elicited Abs to 
the highly conserved HA stalk domain (Krammer et al., 2013; Malherbe et al., 2011; 
Wang et al., 2010; Wei et al., 2010).  However, our study differs from these in that we 
sequentially exposed mice with virus that had an intact but mutated HA head domain of 
the same HA subtype, and we examine the response after a second exposure.  This 
suggests that the head domains may need to be more structurally distinct or that more 
repetitive vaccination may be required to elicit HA stalk-specific Ab responses.  In our 
system, many of the Abs recalled at this early stage by S12a vaccination had a high 
affinity for the priming PR8 strain, but a low or immeasurable affinity for the S12a strain. 
This was in contrast to vaccination with a completely unrelated influenza strain such as 
B/Lee/1940, or an influenza strain that expressed an H3 HA (J1, A/HK/1/68 HA) which 
failed to recall PR8-specific cells into a secondary response despite eliciting new non 
cross-reactive Abs.  This suggests that a certain degree of cross-reactivity is required, 
the threshold of which is still unknown.   
Unexpected protection is elicited by low affinity antibodies 
We found that B cell clones with very low to immeasurable affinity to the boosting 
strain can be recalled in secondary responses and that these clones may provide early 
protection in vivo to the boosting strain.  This demonstrates the sensitivity of the BCR in 
recognizing antigen, and also the ability of soluble Abs to protect even with low affinity 
binding. How these Abs manage to neutralize virus despite their low affinity is yet to be 
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elucidated.  Studies have shown that in vivo components of the immune system such as 
complement and Fc receptors enhance influenza-specific Ab mediated protection, 
particularly for Abs that are broadly cross-reactive or fail to neutralize in vitro (Feng et 
al., 2002).  Several mouse models can be used to determine the role of these 
components in enhancing the low affinity Ab mediated protection evidenced in our work.  
While we transferred our mAbs into WT BALB/c mice, mice that have particular Fc 
receptor genes knocked out (such as FcRγ-/-, FcγRI-/-, FcγRIIb-/-, FcγRIII-/-, FcγRIV-/-, 
or FcRn-/- mice) can be used to test the contribution of particular receptors on the 
neutralization capability of specific Abs. In addition, recombinant mAbs can be 
engineered with Fc region mutations that abrogate or enhance binding of the Fc region 
to particular Fc receptors (DiLillo et al., 2014).  Complement component C1q can also 
affect influenza virus-specific Ab mediated neutralization (Feng et al., 2002).  The effect 
of C1q on Ab mediated neutralization can be tested by in vitro neutralization assays with 
purified C1q protein or using a C1q knockout mouse (Warren et al., 2002). 
In addition to providing early protection, the recall of OAS Abs in a secondary 
response may have additional benefits.  During a primary Ab response, autoreactive B 
cell clones are negatively selected while antigen-specific B cell clones are positively 
selected (Hande et al., 1998).  While OAS clones may still reenter germinal centers and 
gain additional somatic mutations that increase their degree of autoreactivity, OAS 
clones which have been previously positively selected for their antigen-specificity may 
outcompete potentially autoreactive naïve clones.  For instance, approximately half of 
the Cb-specific clones in the primary response to PR8 virus in BALB/c mice are encoded 
by a single Vk gene and one of two closely related VH genes (Kavaler et al., 1990).  This 
group of B cell clones is excluded from the germinal center and does not form a memory 
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response (Kavaler et al., 1991; Rothaeusler and Baumgarth, 2010).  Of note, one 
mechanism of inducing self tolerance is to exclude autoreactive B cell clones from the B 
cell follicle (Cyster et al., 1994; Mandik-Nayak et al., 1997).  This particular group of B 
cell clones is not evident after secondary exposure, potentially due to it being 
outcompeted by recalled MBCs that are poised to respond rapidly to antigen (Kavaler et 
al., 1991).  Recall of cross-reactive and OAS clones from the MBC repertoire may limit 
the activation of potentially autoreactive B cell clones in a similar manner as its exclusion 
of this particular set of Cb-specific B cell clones that are excluded from the memory 
response for an as yet unknown reason.                 
The effect of previous exposure on de novo antibody responses     
We found that while S12a vaccination was able to boost a PR8-specific Ab 
response, this did not come at the cost of S12a-specific Ab titers.  While our attention 
has been focused on the PR8-specific Abs recalled by S12a vaccination, we also 
isolated mAbs that were S12a-specific with immeasurable binding for PR8.  These 
mAbs, isolated 3 days after S12a exposure, were all IgM isotype Abs.  We hypothesize 
that these are early primary response Abs arising from previously naïve B cell clones.  
Due to the limited number of primary clones that we isolated at this early time point, we 
did not fully map the binding footprints of these mAbs.  However, future studies should 
determine if the primary S12a-specific Ab repertoire is significantly affected by previous 
exposure to an antigenically distinct influenza virus.  This could be done by expanding 
the panel of suspected primary S12a mAbs elicited in PR8 strain pre-exposed mice and 
comparing the binding footprints with S12a-specific primary mAbs elicited in previously 
naïve mice.  Should there be a difference in specificity of Abs from PR8 strain pre-
exposed mice, this could be due to competition for antigen or due to epitope shielding by 
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soluble Abs.  Epitope shielding has been predicted to modify the fine specificity of the Ab 
response in a number of disease models (Tsouchnikas et al., 2015).  To test whether 
competition for antigen affects the fine specificity of the response, one would first 
determine if there is an antigen dose dependent effect.  As an additional control, one 
should compare S12a “primary” hybridomas from mice pre-exposed to the J1 strain 
which has a very distinct H3 HA and fails to recall PR8-specific clones as S12a can.  
Finally, one can analyze the “primary” S12a Ab repertoire in PR8 virus pre-exposed 
transgenic mice that fail to secrete soluble Ab to determine the effect of influenza virus-
specific soluble Ab on the development of a de novo primary response to an 
antigenically drifted strain.  These experiments would elucidate the potential effects of 
previous influenza virus exposure on the Ab repertoire developed in response to a novel, 
antigenically drifted influenza strain.      
Maintaining diversity in the memory B cell repertoire 
Our studies show that boosting sequentially vaccinating mice with antigenically 
drifted strains of influenza shaped a repertoire that included not only highly cross-
reactive B cell clones, but also B cell clones that appeared to be specific for a single 
strain.  This raises the question of how a diverse influenza-specific repertoire is 
maintained.  We know that influenza-specific Abs can last a lifetime in humans, with Abs 
specific for the 1918 influenza pandemic strain still measurable in the very elderly 
(Krause et al., 2010).  In fact, these Abs appear to be protective as evidenced by the 
protection of the elderly to the 2009 pH1N1 strain that exhibited some cross-reactivity to 
the 1918 pandemic strain (Ikonen, 2010).  Despite this, new influenza-specific Abs are 
frequently acquired.  There has been evidence that there is competition for a plasma cell 
niche in the bone marrow that provides survival signals to long-lived plasma cells that 
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periodically makes room for new plasma cells while still maintaining memory (Radbruch 
et al., 2006).  Our studies show that the S12a strain can recall clones not only specific 
for itself but also those clones that have a low affinity for S12a and bind predominantly to 
a previously encountered strain.  Similar evidence has been found in humans where 
recent influenza strains are shown to boost the titers of previously circulating strains 
(Fonville et al., 2014).  This may be an important mechanism to broaden the influenza 
repertoire and enhance protection to future strains.  
  In addition, recent research suggests that the majority of MBCs exit the germinal 
center earlier than most long-lived plasma cells (Weisel et al., 2016).  This suggests that 
although some memory cells are highly somatically mutated and may be recalled to 
diverse strains, many MBCs may not be as strain-specific as their highly mutated long-
lived plasma cell relatives.  This could impact the immune repertoire as highly specific 
long-lived plasma cells can provide protection in the form of secreted Ab, while the 
influenza-specific MBC population may remain less mutated but poised to rapidly mutate 
in the necessary direction to create strain-specific immunity.      
New epitopes are potentially elicited by sequential exposure 
While many mAbs have been mapped to the surface of HA by mutant selection, 
the antigenic sites previously described are by no means complete representations of 
potential epitopes.  As most antigenic site determination has relied on analysis of viral 
mutants, residues that are functionally constrained and residues bound by non-
neutralizing Abs that don’t positively select for viral mutants are potentially overlooked.   
Therefore, the previously described antigenic sites likely represent the binding sites of 
the dominant neutralizing Abs, but not necessarily non-neutralizing Abs or Abs that bind 
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to highly conserved sites.  These neglected groups can have important consequences 
for the immune response.  Abs that bind to highly conserved sites are of particular 
interest as they have the potential to be more broadly cross-reactive and may therefore 
protect against a wider range of antigenically drifted strains of influenza.   
Non-neutralizing Abs may also play an important role in susceptibility to infection.  
Little is known regarding the proportion of non-neutralizing Abs that is elicited in 
response to vaccination, infection, or sequential exposure.  To determine the footprints 
of non-neutralizing antibodies, one could follow one of two approaches.  First, one could 
introduce mutations throughout the HA, not only in those sites previously isolated after 
incubation with neutralizing antibodies, and test reactivity of non-neutralizing Abs to this 
expanded panel.  This would however exclude those non-neutralizing Abs that bind to 
epitopes that are highly conserved due to functional constraints.  Second, one could co-
crystallize Abs with HA to determine the binding site of non-neutralizing Abs that bind to 
a highly conserved site.  Such non-neutralizing Abs could be physiologically important as 
they could be recalled after sequential exposure without contributing to neutralization.    
While the majority of both the PR8 strain-specific and cross-reactive mAbs that 
were elicited in our experiments bound to previously defined regions of the HA head, a 
number of mAbs bound to all of the viral mutants in our antigenic map panel.  As our 
viral mutant panel is not exhaustive, these mAbs may bind to previously defined 
epitopes that are not addressed by our panel, or these mAbs may require more than one 
mutation in their footprint to abrogate binding.  However, there is also the possibility that 
these mAbs bind outside of the previously dominant antigenic sites.  Preliminary results 
using recombinant chimeric HA suggest that the unmapped mAbs in our studies are not 
HA stalk binding mAbs.  A number of approaches can be used to define the presently 
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unclear binding footprint of these mAbs.  PR8-specific mAbs that fail to bind S12a can 
be tested by ELISA against a panel of sequential mutants that contain between 1 and 13 
mutations present in S12a to determine which of the mutations in the S12a strain 
abrogate binding.  This will be particularly informative as it may be necessary for several 
mutations to be in place before the mAb fails to bind.  Cross-reactive mAbs that bind to 
both the PR8 and S12a strains can be incubated with virus to isolate viral mutants that 
abrogate mAb binding to determine the possible locations of the binding footprint.  This 
footprint could then be tested and expanded by additional ELISAs using viruses 
engineered to have mutations in those regions.  Should these mAbs fail to neutralize 
virus in vitro, it will not be possible to isolate viral escape mutants in this manner.  
Instead, these mAbs can be tested against a panel of antigenically drifted viral isolates 
that have circulated since the PR8 strain was first isolated in 1934 to determine if any 
mutations have been randomly acquired throughout time that abrogate binding of these 
cross-reactive mAbs.   
A potential mechanism for OAS      
We have found that even PR8 strain-specific clones that have very low affinity for 
the S12a strain are recalled into a secondary Ab response following an S12a 
vaccination.  Many of these clones have immeasurable affinity by ELISA.  However, 
previous studies have shown that the sensitivity of the BCR can be much greater than 
that of soluble Ab (Lingwood et al., 2012).  While the somatically mutated soluble Abs 
tested have measurable affinity for antigen, soluble Abs using the germline sequence do 
not.  The germline Abs tested do however bind to antigen when expressed on the cell 
surface as BCR.  We hypothesize that S12a virus immunization is able to recall PR8 
strain-specific Abs despite their low affinity for the S12a strain because the BCR has an 
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increased sensitivity to the S12a virus HA in comparison to soluble Ab.  Preliminary 
results in our laboratory have shown that plate-bound PR8-specific mAbs elicited in PR8 
strain pre-exposed mice boosted with the S12a strain have a higher relative affinity for 
S12a virus HA than soluble mAb.  This suggests that the conformation of Ab on a 
surface can increase the avidity of PR8 strain-specific mAbs for S12a virus.  To test this 
hypothesis more meticulously in a more physiological setting, PR8 strain-specific mAbs 
with immeasurable S12a-specific affinity can be artificially expressed on the cell surface 
and binding to soluble antigen can be assessed by fluorescent antigen or by calcium 
indicator.  This will indicate whether PR8 strain-specific mAbs recalled by S12a virus 
vaccination bind to S12a virus when expressed in a membrane bound form.  This is of 
significance to the field of B cell immunity as it calls into question the sensitivity and 
comprehensiveness of analyses that measure the Ab repertoire using soluble Abs.     
The effect of previous influenza virus exposure on influenza virus susceptibility 
While our studies in a mouse model highlight how the fine specificities of Abs 
change after sequential exposure and outlines a potential protective role for OAS Abs, 
humans are continuously exposed to antigenically drifted strains of influenza that have 
varying degrees of similarity.  In 2009, a new pH1N1 strain quickly replaced the 
previously circulating sH1N1 strain.  The pH1N1 strain has a highly dissimilar head 
domain compared to previously circulating sH1N1 strains and has continued to 
accumulate mutations over time.   
During the 2013-2014 influenza season, middle-aged adults were found to have 
an increased influenza disease burden.  Studies have shown that different age groups 
have different influenza-specific Ab repertoires.  We hypothesize that the age-specific 
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increase in susceptibility in the 2013-2014 influenza season is due to a recently acquired 
mutation that abrogates Abs prevalent in middle-aged adults due to their unique pre-
exposure history.  We find that human serum samples from middle-aged adults are more 
likely to exhibit reduced binding and neutralization against a mutant virus that contains 
the recently acquired K166Q HA mutation.  mAbs that fail to bind to K166Q HA mutant 
influenza virus also fail to protect mice against infection with a K166Q HA mutant virus in 
an in vivo passive transfer experiment.  These results suggest that an Ab repertoire 
focused on this newly mutated region negatively affects protection against infection.   
We hypothesize that the K166 HA-specific Abs affected by the recent K166Q HA 
mutation are expressed by B cells that are the progeny of B cells previously elicited by 
sH1N1 strains.  This is supported by analysis of human serum samples collected before 
and after immunization with the 2009 pH1N1 strain.  This analysis shows that 
vaccination of middle-aged adults with the 2009 pH1N1 strain elicits an Ab response in 
some individuals that has reduced binding to a pH1N1 strain engineered to have a 
K166Q HA mutation.  In addition, pH1N1 infected ferrets previously infected with a 
sH1N1 strain that circulated in the early 1980s (when middle-aged individuals were 
young) are more likely to have an Ab response that exhibits reduced binding to the new 
K166Q HA mutant strain.  Taken together, these results suggest that while previous 
exposure shifts the Ab response to epitopes conserved between sequentially circulating 
viral strains, the shift in epitope immunodominance can affect susceptibility should a 
previously conserved region acquire a mutation by continued antigenic drift.   
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Updating the antibody repertoire 
Our work suggests that a new mutation has been acquired by circulating pH1N1 
strains that abrogates binding of Abs commonly prevalent in middle-aged adults.  We 
therefore recommend that the H1N1 component of the influenza vaccine be updated to 
include a currently circulating strain that has a K166Q HA mutation.  However, we do not 
know whether individuals vaccinated or infected with a Q166 HA viral strain will produce 
protective Abs to this epitope, or whether the antibody response will be shifted to a 
different region of the HA.  To test whether an updated strain would elicit Q166-specific 
Abs in these individuals, serum samples collected before and after vaccination or natural 
infection with a Q166 HA viral strain should be analyzed by HAI assay and by in vitro 
neutralization assay. This will illustrate how efficiently exposure to a highly similar 
influenza strain with a relevant antigenic mutation can update an Ab repertoire that is 
focused on a recently mutated site.    
Understanding B cell immunodominance   
We propose that the H1N1 component of the influenza vaccine be updated 
despite the fact that more conventional surveillance techniques that use primary ferret 
sera fail to determine that the K166Q HA mutation is antigenically relevant.  We suggest 
that this is due to the fact that the primary Ab response in previously naïve ferrets 
infected with the pH1N1 strain is focused on a region of the HA encompassing HA 
residues 156, 157, and 158 that is not affected by a mutation at residue 166 (Li et al., 
2013).  Why epitopes containing residues 156-158 of the HA are immunodominant for 
the ferret Ab response to the pH1N1 strain is currently unknown.  In fact, the mechanism 
of B cell immunodominance is largely unexplained.  Unraveling this mystery would be of 
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great value to future vaccine design and the understanding of the B cell response to 
infection, autoimmunity, and tumor antigens.   
Immunodominance is not permanent and can be shifted from one epitope to 
another.  In fact, shifting humoral immunodominance to subdominant but broadly 
neutralizing epitopes is the strategy of a number of experimental universal influenza 
vaccines.  However, although it has been possible to shift the immune response to 
conserved epitopes like the HA stalk, this has been a transient effect as re-infection or 
immunization of an individual tends to shift the Ab response back to the dominant HA 
head domain epitopes (Andrews et al., 2015; Ellebedy et al., 2014).  It has been 
suggested that subdominant epitopes only become dominant when they are recalled in 
the absence of competition from previously elicited clones to typically dominant epitopes.  
This would explain why previously subdominant HA stalk-specific B cell clones become 
more prevalent in humans who are infected or immunized with the 2009 pH1N1 strain 
which has an extensively mutated HA head domain in comparison to previously 
circulating sH1N1 strains (Wrammert et al., 2011).  This is also hypothesized to be the 
reason why sequentially immunizing mice with HA that have conserved HA stalk 
domains but highly diverse head domains shifts the Ab response towards the stalk 
domain (Ellebedy et al., 2014; Krammer et al., 2013).  However, while previously elicited 
B cell clones specific for subdominant epitopes may be temporarily dominant, the 
repertoire remains diverse.  Once exposed to an HA head domain, new B cell clones 
specific for those dominant epitopes arise and these can once again outcompete B cell 
clones that are specific for subdominant epitopes.  This would explain why the HA stalk-
specific response in individuals who are infected or immunized with the 2009 pH1N1 
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strain lose immunodominance against the HA stalk domain after a second exposure to 
the pH1N1 strain (Andrews et al., 2015). 
If one could limit the repertoire to broadly cross-reactive clones, those clones that 
are specific for the dominant but more strain-specific epitopes would not outcompete the 
subdominant broadly cross-reactive clones.  However, to make this a possibility, one 
would not only need to create a vaccine that lacks the previously dominant epitopes, but 
it would also have to be so strongly neutralizing that any natural exposure to circulating 
influenza strains would fail to mount a de novo Ab response to the dominant but variable 
head domain as any Ab response to more dominant epitopes would eventually 
outcompete the more broadly neutralizing subdominant clones.  This has been 
attempted in the form of “headless” HA vaccines (Steel et al., 2010; Uranowska, 2014; 
Yassine et al., 2015).  The HA protein is initially expressed as an HA0 protein which is 
later cleaved into the HA1 and HA2 subunits.  These two subunits are bound together by 
disulfide bounds.  The HA head domain is encoded entirely by the HA1 region, while the 
HA stalk domain is encoded by both the HA1 and HA2 subunits.  Should these subunits 
separate, the head domain remains intact while the stalk domain is incomplete.  HA1 
subunits have been shown to induce an Ab response, whereas the HA2 subunit has not 
(Khurana et al., 2011b; Sguazza et al., 2013).  This could potentially affect 
immunodominance of the head domain and reduced immunogenicity of the stalk domain 
should the disulfide bonds be cleaved in vivo (Hogg, 2003).  The headless HA constructs 
that have been artificially created contain the HA2 subunit and the region of HA1 that 
contributes to the HA stalk domain while excluding the region that encodes the HA head 
domain.  Interestingly, sera collected from mice immunized with “headless” HA failed to 
neutralize virus in in vitro neutralization assays, but these mice were protected against in 
	
	
104 
vivo challenge with a homologous virus (Steel et al., 2010).  This contrast might be 
explained in light of recent results that demonstrate that many stalk-specific Abs require 
Fc receptor binding for neutralization activity (DiLillo et al., 2014).  However, while these 
headless HA constructs initially elicited an Ab response that was more broadly cross-
reactive in a subset of vaccinated mice, whether this remained true after viral challenge 
remains unaddressed.  Based on our current experience with pH1N1 infections, this 
appears to be unlikely, underscoring the need to more fully understand the mechanisms 
of B cell immunodominance.      
Concluding Thoughts 
 The observation of OAS has been paradoxical to the theory of clonal selection as 
an antigenically drifted strain of influenza virus recalls B cell clones specific for a 
previously circulating strain that appear to fail to bind to the new, drifted strain.  
However, we know that a certain degree of cross-reactivity is required.  While we might 
expect antigen to induce the recall of the strongest affinity B cell clones, antigenically 
drifted strains of influenza can recall B cell clones that have extremely low affinity for the 
new drifted strain relative to the affinity to an older strain.  While this can occur at the 
expense of mounting a de novo Ab response to the drifted strain in the case of 
sequential infection, in our experiments there is no detrimental effect on overall titers to 
the drifted strain after sequential vaccination with inactivated virus.  In addition, the OAS 
Abs elicited after recall by a drifted strain can have a positive effect on protection and 
this can be further affected by somatic hypermutation.  However, while we show that 
OAS Abs can contribute to a protective immune response, shifting the Ab response 
towards regions conserved between the previously experienced strains can potentially 
affect individual susceptibility to infection to further drifted strains.  We show that an HA 
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mutation, K166Q, negatively affects binding of human sera of middle-aged adults and 
that a K166 HA-specific mAb isolated from a middle-aged adult fails to neutralize K166Q 
HA mutant viruses.  This therefore highlights the pros and cons of shifting the Ab 
repertoire in response to sequential exposure to antigenically drifted strains of influenza 
virus (Figure 21).  The challenge of future endeavors in this field will be to determine 
how to manipulate these repertoire changes to elicit the Abs of choice against not only 
influenza virus, but also other difficult targets, such as HIV and tumor antigens.  Our 
ability to design more effective vaccines and antibody therapies will continue to improve 
as we put together piece by piece the puzzle that is Ab immunodominance and the ever-
shifting Ab repertoire.       
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Figure 21 
 
Figure 21.  A schematic diagram of the effect of sequential exposure to 
antigenically drifted strains of influenza on the specificity and function of the Ab 
repertoire 
(A) A primary HA-specific B cell response to a particular ‘blue’ strain elicits Abs that are 
predominantly strain-specific (represented by a light shade) and not highly cross-reactive 
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(represented by a darker shade).  (B) After a secondary response to the same ‘blue’ 
strain, Ab specificity may shift to other epitopes, but the B cell clones remain 
predominantly strain-specific, with only a slight increase in the degree of cross-reactivity 
to antigenically drifted strains.  (C) In contrast, the fine specificity of B cell clones elicited 
by heterologous exposure differs from those elicited by a homologous recall response.  
Individuals who are pre-exposed to the ‘blue’ strain and then boosted with an 
antigenically distinct ‘green’ strain elicit not only a de novo Ab response against the 
‘green’ strain, but also recall Abs previously elicited by the ‘blue’ strain that have varying 
degrees of cross-reactivity. There is an increased proportion of B cell clones expressing 
highly cross-reactive Abs, but also recall of B cell clones expressing Abs with a higher 
affinity for the ‘blue’ strain than the ‘green’ strain.  Many of these Abs with a higher 
affinity to the priming ‘blue’ strain are protective against the ‘green’ strain.  However, the 
shift in Ab fine specificity after sequential exposure not only affects cross-reactivity and 
protection against the ‘green’ strain, but may affect susceptibility to a novel antigenically 
drifted strain that has a mutation that abrogates binding of these Abs.      
 
	
	
	
	
	
	
	
	
	
	
	
108 
BIBLIOGRAPHY 
 
Allen, C.D.C., Okada, T., Tang, H.L., and Cyster, J.G. (2007). Imaging of Germinal 
Center Selection Events During Affinity Maturation. Science 315, 528-531. 
Alt, F.W., and Baltimore, D. (1982). Joining of immunoglobulin heavy chain gene 
segments: implications from a chromosome with evidence of three D-JH fusions. 
Proceedings of the National Academy of Sciences of the United States of America 79, 
4118-4122. 
Altman, M.O., Bennink, J.R., Yewdell, J.W., and Herrin, B.R. (2015). Lamprey VLRB 
response to influenza virus supports universal rules of immunogenicity and antigenicity. 
eLife 4, e07467. 
Anderson, S.M., Khalil, A., Uduman, M., Hershberg, U., Louzoun, Y., Haberman, A.M., 
Kleinstein, S.H., and Shlomchik, M.J. (2009). Taking Advantage: High-Affinity B Cells in 
the Germinal Center Have Lower Death Rates, but Similar Rates of Division, Compared 
to Low-Affinity Cells. The Journal of Immunology 183, 7314-7325. 
Andrews, S.F., Huang, Y., Kaur, K., Popova, L.I., Ho, I.Y., Pauli, N.T., Dunand, C.J.H., 
Taylor, W.M., Lim, S., Huang, M., et al. (2015). Immune history profoundly affects 
broadly protective B cell responses to influenza. Science Translational Medicine 7, 
316ra192-316ra192. 
Arriola, C.S.B., Lynnette; Epperson, Scott; Blanton, Lenee; Kniss, Krista; Mustaquim, 
Desiree; Steffens, Craig; Dhara, Rosaline; Leon, Michelle; Perez, Alejandro; Chaves, 
Sandra S.; Katz, Jackie; Wallis, Teresa; Villanueva, Julie; Xu, Xiyan; Isa Abd Elal, 
Anwar; Gubareva, Larisa; Cox, Nancy; Finelli, Lyn; Bresee, Joseph; Jhung, Michael; 
(2014). Update: Influenza Activity - United States, September 29, 2013 - February 8, 
2014. Morbidity and Mortality Weekly Report 63, 148-154. 
Bao, Y., Bolotov, P., Dernovoy, D., Kiryutin, B., Zaslavsky, L., Tatusova, T., Ostell, J., 
and Lipman, D. (2008). The Influenza Virus Resource at the National Center for 
Biotechnology Information. Journal of Virology 82, 596-601. 
Berry, J.D., Peeling, R.W., and Brunham, R.C. (1999). Analysis of the Original Antigenic 
Sin Antibody Response to the Major Outer Membrane Protein of Chlamydia trachomatis. 
Journal of Infectious Diseases 179, 180-186. 
Bodewes, R., de Mutsert, G., van der Klis, F.R., Ventresca, M., Wilks, S., Smith, D.J., 
Koopmans, M., Fouchier, R.A., Osterhaus, A.D., and Rimmelzwaan, G.F. (2011). 
	
	
109 
Prevalence of antibodies against seasonal influenza A and B viruses in children in 
Netherlands. Clin Vaccine Immunol 18, 469-476. 
Briney, B.S., and Crowe, J.E. (2013). Secondary Mechanisms of Affinity Maturation in 
the Human Antibody Repertoire. Frontiers in Immunology 4. 
Burnet, F.M. (1957). A Modificationof Jerne's Theory of Antibody Production using the 
Concept of Clonal Selection. The Australian Journal of Science 20, 67-69. 
Bush, R.M., Bender, C.A., Subbarao, K., Cox, N.J., and Fitch, W.M. (1999). Predicting 
the Evolution of Human Influenza A. Science 286, 1921-1925. 
Butcher, E.C., and Picker, L.J. (1996). Lymphocyte Homing and Homeostasis. Science 
272, 60-67. 
Caton, A.J., Brownlee, G.G., Yewdell, J.W., and Gerhard, W. (1982). The Antigenic 
Structure of the Influenza-Virus A/pr/8/34 Hemagglutinin (H-1 Subtype). Cell 31, 417-
427. 
Cattaneo, A., and Neuberger, M.S. (1987). Polymeric immunoglobulin M is secreted by 
transfectants of non-lymphoid cells in the absence of immunoglobulin J chain. The 
EMBO Journal 6, 2753-2758. 
Chambers, B.S., Parkhouse, K., Ross, T.M., Alby, K., and Hensley, S.E. (2015). 
Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 
2014-2015 Influenza Season. Cell Rep 12, 1-6. 
Chen, Z., Wang, W., Zhou, H., Suguitan, A.L., Shambaugh, C., Kim, L., Zhao, J., 
Kemble, G., and Jin, H. (2010). Generation of Live Attenuated Novel Influenza Virus 
A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs. 
Journal of Virology 84, 44-51. 
Ciupe, S.M., De Leenheer, P., and Kepler, T.B. (2011). Paradoxical suppression of poly-
specific broadly neutralizing antibodies in the presence of strain-specific neutralizing 
antibodies following HIV infection. Journal of Theoretical Biology 277, 55-66. 
Clegg, C.H., Roque, R., Van Hoeven, N., Perrone, L., Baldwin, S.L., Rininger, J.A., 
Bowen, R.A., and Reed, S.G. (2012). Adjuvant solution for pandemic influenza vaccine 
production. Proceedings of the National Academy of Sciences 109, 17585-17590. 
	
	
110 
Cooper, L.J., Shikhman, A.R., Glass, D.D., Kangisser, D., Cunningham, M.W., and 
Greenspan, N.S. (1993). Role of heavy chain constant domains in antibody-antigen 
interaction. Apparent specificity differences among streptococcal IgG antibodies 
expressing identical variable domains. The Journal of Immunology 150, 2231-2242. 
Council, N.R. (2011). Guide for the Care and Use of Laboratory Animals, 8th Ed. edn 
(Washington, DC: National Acadamies Press). 
Cyster, J.G., Hartley, S.B., and Goodnow, C.C. (1994). Competition for follicular niches 
excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371, 389-395. 
Das, Suman R., Hensley, Scott E., Ince, William L., Brooke, Christopher B., Subba, A., 
Delboy, Mark G., Russ, G., Gibbs, James S., Bennink, Jack R., and Yewdell, 
Jonathan W. (2013). Defining Influenza A Virus Hemagglutinin Antigenic Drift by 
Sequential Monoclonal Antibody Selection. Cell Host & Microbe 13, 314-323. 
Davenport, F.M., and Hennessy, A.V. (1956). A SEROLOGIC RECAPITULATION OF 
PAST EXPERIENCES WITH INFLUENZA A; ANTIBODY RESPONSE TO 
MONOVALENT VACCINE. The Journal of Experimental Medicine 104, 85-97. 
Davenport, F.M., Hennessy, A.V., Francis, T., and With the Technical Assistance of 
Phyllis, F. (1953). EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE 
DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS. 
The Journal of experimental medicine 98, 641-656. 
de St.Groth, S.F., and Webster, R.G. (1966a). DISQUISITIONS ON ORIGINAL 
ANTIGENIC SIN. The Journal of experimental medicine 124, 331-345. 
de St.Groth, S.F., and Webster, R.G. (1966b). DISQUISITIONS ON ORIGINAL 
ANTIGENIC SIN: II. PROOF IN LOWER CREATURES. The Journal of Experimental 
Medicine 124, 347-361. 
Deenick, E.K., Avery, D.T., Chan, A., Berglund, L.J., Ives, M.L., Moens, L., Stoddard, 
J.L., Bustamante, J., Boisson-Dupuis, S., Tsumura, M., et al. (2013). Naive and memory 
human B cells have distinct requirements for STAT3 activation to differentiate into 
antibody-secreting plasma cells. The Journal of Experimental Medicine 210, 2739-2753. 
Deutsch, S., Vinit, M.-A., and Bussard, A.E. (1973). Original antigenic sin at the cellular 
level. II. Specificity of the antibodies produced by individual cells. European Journal of 
Immunology 3, 235-240. 
	
	
111 
DiLillo, D.J., Tan, G.S., Palese, P., and Ravetch, J.V. (2014). Broadly neutralizing 
hemagglutinin stalk-specific antibodies require Fc[gamma]R interactions for protection 
against influenza virus in vivo. Nat Med 20, 143-151. 
Dogan, I., Bertocci, B., Vilmont, V., Delbos, F., Megret, J., Storck, S., Reynaud, C.-A., 
and Weill, J.-C. (2009). Multiple layers of B cell memory with different effector functions. 
Nat Immunol 10, 1292-1299. 
Dreyfus, C., Ekiert, D.C., and Wilson, I.A. (2013). Structure of a Classical Broadly 
Neutralizing Stem Antibody in Complex with a Pandemic H2 Influenza Virus 
Hemagglutinin. Journal of Virology 87, 7149-7154. 
Drummond, A.J., Suchard, M.A., Xie, D., and Rambaut, A. (2012). Bayesian 
Phylogenetics with BEAUti and the BEAST 1.7. Molecular Biology and Evolution 29, 
1969-1973. 
Early, P., Huang, H., Davis, M., Calame, K., and Hood, L. (1980). An immunoglobulin 
heavy chain variable region gene is generated from three segments of DNA: VH, D and 
JH. Cell 19, 981-992. 
Edelman, G.M. (1973). Antibody Structure and Molecular Immunology. Science 180, 
830-840. 
Eisen, H.L., JR; Steiner, LA; Simms, ES; Gray, W (1969). Degeneracy in the secondary 
immune response: stimulation of antibody formation by cross-reacting antigens. Isreal 
Journal of Medical Sciences 5, 338-351. 
Ekiert, D.C., Bhabha, G., Elsliger, M.-A., Friesen, R.H.E., Jongeneelen, M., Throsby, M., 
Goudsmit, J., and Wilson, I.A. (2009). Antibody Recognition of a Highly Conserved 
Influenza Virus Epitope. Science 324, 246-251. 
Ellebedy, A.H., Krammer, F., Li, G.-M., Miller, M.S., Chiu, C., Wrammert, J., Chang, 
C.Y., Davis, C.W., McCausland, M., Elbein, R., et al. (2014). Induction of broadly cross-
reactive antibody responses to the influenza HA stem region following H5N1 vaccination 
in humans. Proceedings of the National Academy of Sciences 111, 13133-13138. 
Engels, N., Konig, L.M., Heemann, C., Lutz, J., Tsubata, T., Griep, S., Schrader, V., and 
Wienands, J. (2009). Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and 
IgE provides antigen receptor-intrinsic costimulation to class-switched B cells. Nat 
Immunol 10, 1018-1025. 
	
	
112 
Fazekas de St, G., and Webster, R.G. (1966). Disquisitions of Original Antigenic Sin. I. 
Evidence in man. J Exp Med 124, 331-345. 
Feng, J.Q., Mozdzanowska, K., and Gerhard, W. (2002). Complement Component C1q 
Enhances the Biological Activity of Influenza Virus Hemagglutinin-Specific Antibodies 
Depending on Their Fine Antigen Specificity and Heavy-Chain Isotype. Journal of 
Virology 76, 1369-1378. 
Fish, S., Zenowich, E., Fleming, M., and Manser, T. (1989). Molecular analysis of 
original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during 
a memory B cell response. The Journal of Experimental Medicine 170, 1191-1209. 
Fonville, J.M., Wilks, S.H., James, S.L., Fox, A., Ventresca, M., Aban, M., Xue, L., 
Jones, T.C., Le N. M. H., Pham Q. T., et al. (2014). Antibody landscapes after influenza 
virus infection or vaccination. Science 346, 996-1000. 
Francis, J.T. (1953). Influenza: The Newe Acquayantance. Annals of Internal Medicine 
39, 203-221. 
Francis, J.T. (1955). THE CURRENT STATUS OF THE CONTROL OF INFLUENZA*. 
Annals of Internal Medicine 43, 534-538. 
Francis, T. (1960). On the Doctrine of Original Antigenic Sin. Proceedings of the 
American Philosophical Society 104, 572. 
Garty, B.Z., Ludomirsky, A., Danon, Y.L., Peter, J.B., and Douglas, S.D. (1994). 
Placental transfer of immunoglobulin G subclasses. Clinical and Diagnostic Laboratory 
Immunology 1, 667-669. 
Gerhard, W., Yewdell, J., Frankel, M.E., and Webster, R. (1981). Antigenic Structure of 
Influenza-Virus Hemagglutinin Defined by Hybridoma Antibodies. Nature 290, 713-717. 
Gitlin, A.D., Shulman, Z., and Nussenzweig, M.C. (2014). Clonal selection in the 
germinal centre by regulated proliferation and hypermutation. Nature 509, 637-640. 
Giudicelli, V., Brochet, X., and Lefranc, M.-P. (2011). IMGT/V-QUEST: IMGT 
Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide 
Sequences. Cold Spring Harbor Protocols 2011, pdb.prot5633. 
	
	
113 
Goff, P.H., Eggink, D., Seibert, C.W., Hai, R., Martínez-Gil, L., Krammer, F., and Palese, 
P. (2013). Adjuvants and Immunization Strategies to Induce Influenza Virus 
Hemagglutinin Stalk Antibodies. PLoS ONE 8, e79194. 
Gray, C., and Tamm, L.K. (1998). pH-induced conformational changes of membrane-
bound influenza hemagglutinin and its effect on target lipid bilayers. Protein Science : A 
Publication of the Protein Society 7, 2359-2373. 
Halstead, S.B., Rojanasuphot, S., and Sangkawibha, N. (1983). Original Antigenic Sin in 
Dengue. The American Journal of Tropical Medicine and Hygiene 32, 154-156. 
Hande, S., Notidis, E., and Manser, T. (1998). Bcl-2 Obstructs Negative Selection of 
Autoreactive, Hypermutated Antibody V Regions during Memory B Cell Development. 
Immunity 8, 189-198. 
Hartley, S.B., Crosbie, J., Brink, R., Kantor, A.B., Basten, A., and Goodnow, C.C. (1991). 
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing 
membrane-bound antigens. Nature 353, 765-769. 
Heaton, N.S., Sachs, D., Chen, C.-J., Hai, R., and Palese, P. (2013). Genome-wide 
mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 
proteins. Proceedings of the National Academy of Sciences of the United States of 
America 110, 20248-20253. 
Hebeis, B.J., Klenovsek, K., Rohwer, P., Ritter, U., Schneider, A., Mach, M., and 
Winkler, T.H. (2004). Activation of Virus-specific Memory B Cells in the Absence of T 
Cell Help. The Journal of Experimental Medicine 199, 593-602. 
Hensley, S.E. (2014). Challenges of selecting seasonal influenza vaccine strains for 
humans with diverse pre-exposure histories. Curr Opin Virol 8C, 85-89. 
Hensley, S.E., Das, S.R., Bailey, A.L., Schmidt, L.M., Hickman, H.D., Jayaraman, A., 
Viswanathan, K., Raman, R., Sasisekharan, R., Bennink, J.R., et al. (2009). 
Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift. Science 
326, 734-736. 
Hilbert, D.M., Cancro, M.P., Scherle, P.A., Nordan, R.P., Van Snick, J., Gerhard, W., 
and Rudikoff, S. (1989). T cell derived IL-6 is differentially required for antigen-specific 
antibody secretion by primary and secondary B cells. The Journal of Immunology 143, 
4019-4024. 
	
	
114 
Hirst, G.K. (1941). The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos 
Infected with Influenza Virus. Science 94, 22-23. 
Hogg, P.J. (2003). Disulfide bonds as switches for protein function. Trends in 
Biochemical Sciences 28, 210-214. 
Hozumi, N., and Tonegawa, S. (1976). Evidence for somatic rearrangement of 
immunoglobulin genes coding for variable and constant regions. Proceedings of the 
National Academy of Sciences of the United States of America 73, 3628-3632. 
Huang, J.-W., Lin, W.-F., and Yang, J.-M. (2012). Antigenic sites of H1N1 influenza virus 
hemagglutinin revealed by natural isolates and inhibition assays. Vaccine 30, 6327-
6337. 
Ibricevic, A., Pekosz, A., Walter, M.J., Newby, C., Battaile, J.T., Brown, E.G., Holtzman, 
M.J., and Brody, S.L. (2006). Influenza Virus Receptor Specificity and Cell Tropism in 
Mouse and Human Airway Epithelial Cells. Journal of Virology 80, 7469-7480. 
Ichinohe, T., Pang, I.K., and Iwasaki, A. (2010). Influenza virus activates inflammasomes 
via its intracellular M2 ion channel. Nat Immunol 11, 404-410. 
Ikonen, N.S., M; Kinnunen, L; Osterlund, P; Perhonen, J; Broman, M; Davidkin, I; 
Ziegler, T; Julkunen, I (2010). High frequency of cross-reacting antibodies against 2009 
pandemic influenza A(H1N1) virus among the elderly in Finland. Eurosurveillance 15. 
Jacob, J., Kassir, R., and Kelsoe, G. (1991a). In situ studies of the primary immune 
response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of 
responding cell populations. The Journal of Experimental Medicine 173, 1165-1175. 
Jacob, J., Kelsoe, G., Rajewsky, K., and Weiss, U. (1991b). Intraclonal generation of 
antibody mutants in germinal centres. Nature 354, 389-392. 
Jones, D.T., Taylor, W.R., and Thornton, J.M. (1992). The rapid generation of mutation 
data matrices from protein sequences. Computer applications in the biosciences : 
CABIOS 8, 275-282. 
Kavaler, J., Caton, A.J., Staudt, L.M., and Gerhard, W. (1991). A B cell population that 
dominates the primary response to influenza virus hemagglutinin does not participate in 
the memory response. European journal of immunology 21, 2687-2695. 
	
	
115 
Kavaler, J., Caton, A.J., Staudt, L.M., Schwartz, D., and Gerhard, W. (1990). A set of 
closely related antibodies dominates the primary antibody response to the antigenic site 
CB of the A/PR/8/34 influenza virus hemagglutinin. The Journal of Immunology 145, 
2312-2321. 
Kawasaki, K., Sato, S.B., and Ohnishi, S.-i. (1983). Membrane fusion activity of 
reconstituted vesicles of influenza virus hemagglutinin glycoproteins. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 733, 286-290. 
Khurana, S., Verma, N., Yewdell, J.W., Hilbert, A.K., Castellino, F., Lattanzi, M., Del 
Giudice, G., Rappuoli, R., and Golding, H. (2011a). MF59 Adjuvant Enhances Diversity 
and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. 
Science Translational Medicine 3, 85ra48-85ra48. 
Khurana, S., Verma, S., Verma, N., Crevar, C.J., Carter, D.M., Manischewitz, J., King, 
L.R., Ross, T.M., and Golding, H. (2011b). Bacterial HA1 Vaccine against Pandemic 
H5N1 Influenza Virus: Evidence of Oligomerization, Hemagglutination, and Cross-
Protective Immunity in Ferrets. Journal of Virology 85, 1246-1256. 
Kim, J.H., Davis, W.G., Sambhara, S., and Jacob, J. (2012). Strategies to alleviate 
original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A 109, 
13751-13756. 
Kim, J.H., Skountzou, I., Compans, R., and Jacob, J. (2009). Original Antigenic Sin 
Responses to Influenza Viruses. The Journal of Immunology 183, 3294-3301. 
Klenerman, P., and Zinkernagel, R.M. (1998). Original antigenic sin impairs cytotoxic T 
lymphocyte responses to viruses bearing variant epitopes. Nature 394, 482-485. 
Klenk, H.-D., Rott, R., Orlich, M., and Blödorn, J. (1975). Activation of influenza A 
viruses by trypsin treatment. Virology 68, 426-439. 
Knossow, M., Gaudier, M., Douglas, A., Barrère, B., Bizebard, T., Barbey, C., Gigant, B., 
and Skehel, J.J. (2002). Mechanism of Neutralization of Influenza Virus Infectivity by 
Antibodies. Virology 302, 294-298. 
Kometani, K., Nakagawa, R., Shinnakasu, R., Kaji, T., Rybouchkin, A., Moriyama, S., 
Furukawa, K., Koseki, H., Takemori, T., and Kurosaki, T. (2013). Repression of the 
transcription factor Bach2 contributes to predisposition of IgG1 memory B cells toward 
plasma cell differentiation. Immunity 39, 136-147. 
	
	
116 
Krammer, F., Pica, N., Hai, R., Margine, I., and Palese, P. (2013). Chimeric 
Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-
Specific Antibodies. Journal of Virology 87, 6542-6550. 
Krause, J.C., Tumpey, T.M., Huffman, C.J., McGraw, P.A., Pearce, M.B., Tsibane, T., 
Hai, R., Basler, C.F., and Crowe, J.E. (2010). Naturally Occurring Human Monoclonal 
Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses. 
Journal of Virology 84, 3127-3130. 
Kucharski, A.J., Lessler, J., Read, J.M., Zhu, H., Jiang, C.Q., Guan, Y., Cummings, D.A., 
and Riley, S. (2015). Estimating the life course of influenza A(H3N2) antibody responses 
from cross-sectional data. PLoS Biol 13, e1002082. 
Lamb, R.A., Zebedee, S.L., and Richardson, C.D. (1985). Influenza virus M2 protein is 
an integral membrane protein expressed on the infected-cell surface. Cell 40, 627-633. 
Lazarowitz, S.G., and Choppin, P.W. (1975). Enhancement of the infectivity of influenza 
A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68, 
440-454. 
Lee, B.O., Moyron-Quiroz, J., Rangel-Moreno, J., Kusser, K.L., Hartson, L., Sprague, F., 
Lund, F.E., and Randall, T.D. (2003). CD40, but Not CD154, Expression on B Cells Is 
Necessary for Optimal Primary B Cell Responses. The Journal of Immunology 171, 
5707-5717. 
Lenschow, D.J., Sperling, A.I., Cooke, M.P., Freeman, G., Rhee, L., Decker, D.C., Gray, 
G., Nadler, L.M., Goodnow, C.C., and Bluestone, J.A. (1994). Differential up-regulation 
of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. 
The Journal of Immunology 153, 1990-1997. 
Li, G.-M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S.F., Zheng, N.-Y., Lee, 
J.-H., Huang, M., Qu, X., Edupuganti, S., et al. (2012). Pandemic H1N1 influenza 
vaccine induces a recall response in humans that favors broadly cross-reactive memory 
B cells. Proceedings of the National Academy of Sciences 109, 9047-9052. 
Li, Y., Myers, J.L., Bostick, D.L., Sullivan, C.B., Madara, J., Linderman, S.L., Liu, Q., 
Carter, D.M., Wrammert, J., Esposito, S., et al. (2013). Immune history shapes 
specificity of pandemic H1N1 influenza antibody responses. The Journal of Experimental 
Medicine 210, 1493-1500. 
	
	
117 
Linderman, S.L., Chambers, B.S., Zost, S.J., Parkhouse, K., Li, Y., Herrmann, C., 
Ellebedy, A.H., Carter, D.M., Andrews, S.F., Zheng, N.-Y., et al. (2014). Potential 
antigenic explanation for atypical H1N1 infections among middle-aged adults during the 
2013–2014 influenza season. Proceedings of the National Academy of Sciences 111, 
15798-15803. 
Lingwood, D., McTamney, P.M., Yassine, H.M., Whittle, J.R.R., Guo, X., Boyington, J.C., 
Wei, C.-J., and Nabel, G.J. (2012). Structural and genetic basis for development of 
broadly neutralizing influenza antibodies. Nature 489, 566-570. 
Liu, W., Chen, E., Zhao, X.W., Wan, Z.P., Gao, Y.R., Davey, A., Huang, E., Zhang, L., 
Crocetti, J., Sandoval, G., et al. (2012). The scaffolding protein synapse-associated 
protein 97 is required for enhanced signaling through isotype-switched IgG memory B 
cell receptors. Sci Signal 5, ra54. 
Liu, Y.-J., Barthélémy, C., Bouteiller, O.D., Arpin, C., Isabelle, D., and Banchereau, J. 
(1995). Memory B cells from human tonsils colonize mucosal epithelium and directly 
present antigen to T cells by Rapid Up-Regulation of B7-1 and B7-2. Immunity 2, 239-
248. 
Lubeck, M.D., and Gerhard, W. (1981). Topological mapping of antigenic sites on the 
influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies. Virology 113, 64-
72. 
Luning Prak, E.T., Monestier, M., and Eisenberg, R.A. (2011). B cell receptor editing in 
tolerance and autoimmunity. Annals of the New York Academy of Sciences 1217, 96-
121. 
Malherbe, D.C., Doria-Rose, N.A., Misher, L., Beckett, T., Puryear, W.B., Schuman, J.T., 
Kraft, Z., O'Malley, J., Mori, M., Srivastava, I., et al. (2011). Sequential Immunization with 
a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of 
Neutralizing Antibodies. Journal of Virology 85, 5262-5274. 
Mandik-Nayak, L., Bui, A., Noorchashm, H., Eaton, A., and Erikson, J. (1997). 
Regulation of Anti–double-stranded DNA B Cells in Nonautoimmune Mice: Localization 
to the T–B Interface of the Splenic Follicle. The Journal of Experimental Medicine 186, 
1257-1267. 
Marshall, N., Priyamvada, L., Ende, Z., Steel, J., and Lowen, A.C. (2013). Influenza 
Virus Reassortment Occurs with High Frequency in the Absence of Segment Mismatch. 
PLoS Pathog 9, e1003421. 
	
	
118 
Martin, S.W., and Goodnow, C.C. (2002). Burst-enhancing role of the IgG membrane tail 
as a molecular determinant of memory. Nat Immunol 3, 182-188. 
Martínez-Sobrido, L., and García-Sastre, A. (2010). Generation of Recombinant 
Influenza Virus from Plasmid DNA. Journal of Visualized Experiments : JoVE, 2057. 
Maruyama, M., Lam, K.-P., and Rajewsky, K. (2000). Memory B-cell persistence is 
independent of persisting immunizing antigen. Nature 407, 636-642. 
Matrosovich, M., Tuzikov, A., Bovin, N., Gambaryan, A., Klimov, A., Castrucci, M.R., 
Donatelli, I., and Kawaoka, Y. (2000). Early Alterations of the Receptor-Binding 
Properties of H1, H2, and H3 Avian Influenza Virus Hemagglutinins after Their 
Introduction into Mammals. Journal of Virology 74, 8502-8512. 
McCown, M.F., and Pekosz, A. (2006). Distinct Domains of the Influenza A Virus M2 
Protein Cytoplasmic Tail Mediate Binding to the M1 Protein and Facilitate Infectious 
Virus Production. Journal of Virology 80, 8178-8189. 
McGeoch, D., Fellner, P., and Newton, C. (1976). Influenza virus genome consists of 
eight distinct RNA species. Proceedings of the National Academy of Sciences of the 
United States of America 73, 3045-3049. 
McHeyzer-Williams, L.J., Milpied, P.J., Okitsu, S.L., and McHeyzer-Williams, M.G. 
(2015). Class-switched memory B cells remodel BCRs within secondary germinal 
centers. Nat Immunol 16, 296-305. 
Mongkolsapaya, J., Dejnirattisai, W., Xu, X.-n., Vasanawathana, S., 
Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S., Duangchinda, T., Dong, T., 
Rowland-Jones, S., et al. (2003). Original antigenic sin and apoptosis in the 
pathogenesis of dengue hemorrhagic fever. Nat Med 9, 921-927. 
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and Honjo, T. 
(2000). Class Switch Recombination and Hypermutation Require Activation-Induced 
Cytidine Deaminase (AID), a Potential RNA Editing Enzyme. Cell 102, 553-563. 
Network, W.H.O.G.I.S. (2011). Manual for the laboratory diagnosis and virological 
surveillance of influenza (World Health Organization). 
	
	
119 
Palese, P., Tobita, K., Ueda, M., and Compans, R.W. (1974). Characterization of 
temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61, 
397-410. 
Palmeira, P., Quinello, C., Silveira-Lessa, A.L., #250, cia, Zago, C., #225, Augusta, u., 
and Carneiro-Sampaio, M. (2012). IgG Placental Transfer in Healthy and Pathological 
Pregnancies. Clinical and Developmental Immunology 2012, 13. 
Pincetic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebiger, 
B.-M., and Ravetch, J.V. (2014). Type I and type II Fc receptors regulate innate and 
adaptive immunity. Nat Immunol 15, 707-716. 
Plotkin, J.B., and Dushoff, J. (2003). Codon bias and frequency-dependent selection on 
the hemagglutinin epitopes of influenza A virus. Proceedings of the National Academy of 
Sciences 100, 7152-7157. 
Plotkin, S.A. (2010). Correlates of Protection Induced by Vaccination. Clinical and 
Vaccine Immunology 17, 1055-1065. 
Radbruch, A., Muehlinghaus, G., Luger, E.O., Inamine, A., Smith, K.G.C., Dorner, T., 
and Hiepe, F. (2006). Competence and competition: the challenge of becoming a long-
lived plasma cell. Nat Rev Immunol 6, 741-750. 
Ramsden, D.A., Paige, C.J., and Wu, G.E. (1994). Kappa light chain rearrangement in 
mouse fetal liver. The Journal of Immunology 153, 1150-1160. 
Reif, K., Ekland, E.H., Ohl, L., Nakano, H., Lipp, M., Forster, R., and Cyster, J.G. (2002). 
Balanced responsiveness to chemoattractants from adjacent zones determines B-cell 
position. Nature 416, 94-99. 
Röhlich, K. (1930). Beitrag zur Cytologie der Keimzentren der Lymphknoten. Zeitschrift 
für mikroskopisch-anatomische Forschung 20, 287-297. 
Rothaeusler, K., and Baumgarth, N. (2010). B cell fate decisions following influenza virus 
infection. European journal of immunology 40, 366-377. 
Sanchez, M., Misulovin, Z., Burkhardt, A.L., Mahajan, S., Costa, T., Franke, R., Bolen, 
J.B., and Nussenzweig, M. (1993). Signal transduction by immunoglobulin is mediated 
through Ig alpha and Ig beta. The Journal of Experimental Medicine 178, 1049-1055. 
	
	
120 
Schultz-Cherry, S., and Jones, J.C. (2010). Influenza vaccines: the good, the bad, and 
the eggs. Adv Virus Res 77, 63-84. 
Sguazza, G.H., Fuentealba, N.A., Tizzano, M.A., Galosi, C.M., and Pecoraro, M.R. 
(2013). Expression of the hemagglutinin HA1 subunit of the equine influenza virus using 
a baculovirus expression system. Revista Argentina de Microbiología 45, 222-228. 
Skehel, J.J., Stevens, D.J., Daniels, R.S., Douglas, A.R., Knossow, M., Wilson, I.A., and 
Wiley, D.C. (1984). A carbohydrate side chain on hemagglutinins of Hong Kong 
influenza viruses inhibits recognition by a monoclonal antibody. Proceedings of the 
National Academy of Sciences 81, 1779-1783. 
Skehel, J.J., and Waterfield, M.D. (1975). Studies on the primary structure of the 
influenza virus hemagglutinin. Proceedings of the National Academy of Sciences of the 
United States of America 72, 93-97. 
Smith, W., Andrewes, C.H., and Laidlaw, P.P. (1933). A VIRUS OBTAINED FROM 
INFLUENZA PATIENTS. The Lancet 222, 66-68. 
Stavnezer, J., Guikema, J.E.J., and Schrader, C.E. (2008). Mechanism and Regulation 
of Class Switch Recombination. Annual review of immunology 26, 261-292. 
Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., García-Sastre, A., 
and Palese, P. (2010). Influenza Virus Vaccine Based on the Conserved Hemagglutinin 
Stalk Domain. mBio 1. 
Stohr, K., Bucher, D., Colgate, T., and Wood, J. (2012). Influenza virus surveillance, 
vaccine strain selection, and manufacture. Methods Mol Biol 865, 147-162. 
Strickland, A. (1903). Life of Mary Queen of Scots (George Bell and Sons). 
Takeda, M., Pekosz, A., Shuck, K., Pinto, L.H., and Lamb, R.A. (2002). Influenza A Virus 
M2 Ion Channel Activity Is Essential for Efficient Replication in Tissue Culture. Journal of 
Virology 76, 1391-1399. 
Takeuchi, K., and Lamb, R.A. (1994). Influenza virus M2 protein ion channel activity 
stabilizes the native form of fowl plague virus hemagglutinin during intracellular 
transport. Journal of Virology 68, 911-919. 
	
	
121 
Tangye, S.G., Avery, D.T., Deenick, E.K., and Hodgkin, P.D. (2003). Intrinsic Differences 
in the Proliferation of Naive and Memory Human B Cells as a Mechanism for Enhanced 
Secondary Immune Responses. The Journal of Immunology 170, 686-694. 
Tas, J.M.J., Mesin, L., Pasqual, G., Targ, S., Jacobsen, J.T., Mano, Y.M., Chen, C.S., 
Weill, J.-C., Reynaud, C.-A., Browne, E.P., et al. (2016). Visualizing antibody affinity 
maturation in germinal centers. Science 351, 1048-1054. 
Thucydides (431 BCE). The History of the Peloponnesian War. 
Tomayko, M.M., Anderson, S.M., Brayton, C.E., Sadanand, S., Steinel, N.C., Behrens, 
T.W., and Shlomchik, M.J. (2008). Systematic Comparison of Gene Expression between 
Murine Memory and Naive B Cells Demonstrates That Memory B Cells Have Unique 
Signaling Capabilities. The Journal of Immunology 181, 27-38. 
Tomayko, M.M., Steinel, N.C., Anderson, S.M., and Shlomchik, M.J. (2010). Cutting 
Edge: Hierarchy of Maturity of Murine Memory B Cell Subsets. The Journal of 
Immunology 185, 7146-7150. 
Toyama, H., Okada, S., Hatano, M., Takahashi, Y., Takeda, N., Ichii, H., Takemori, T., 
Kuroda, Y., and Tokuhisa, T. (2002). Memory B Cells without Somatic Hypermutation 
Are Generated from Bcl6-Deficient B Cells. Immunity 17, 329-339. 
Tsouchnikas, G., Zlatkovic, J., Jarmer, J., Strauß, J., Vratskikh, O., Kundi, M., Stiasny, 
K., and Heinz, F.X. (2015). Immunization with Immune Complexes Modulates the Fine 
Specificity of Antibody Responses to a Flavivirus Antigen. Journal of Virology 89, 7970-
7978. 
Tudor, D., Yu, H., Maupetit, J., Drillet, A.-S., Bouceba, T., Schwartz-Cornil, I., Lopalco, 
L., Tuffery, P., and Bomsel, M. (2012). Isotype modulates epitope specificity, affinity, and 
antiviral activities of anti–HIV-1 human broadly neutralizing 2F5 antibody. Proceedings of 
the National Academy of Sciences 109, 12680-12685. 
Ueno, T., Idegami, Y., Motozono, C., Oka, S., and Takiguchi, M. (2007). Altering Effects 
of Antigenic Variations in HIV-1 on Antiviral Effectiveness of HIV-Specific CTLs. The 
Journal of Immunology 178, 5513-5523. 
Uranowska, K.T., J; Jurek, A; Szewczyk, B; Gromadzka, B; (2014). Hemagglutinin stalk 
domain from H5N1 strain as a potentially universal antigen. Acta Biochimica Polonica 
61, 541-550. 
	
	
122 
Van de Perre, P. (2003). Transfer of antibody via mother’s milk. Vaccine 21, 3374-3376. 
Vettermann, C., and Schlissel, M.S. (2010). Allelic exclusion of immunoglobulin genes: 
models and mechanisms. Immunological reviews 237, 22-42. 
Victora, G.D., Schwickert, T.A., Fooksman, D.R., Kamphorst, A.O., Meyer-Hermann, M., 
Dustin, M.L., and Nussenzweig, M.C. (2010). Germinal Center Dynamics Revealed by 
Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter. Cell 143, 592-
605. 
Virelizier, J.-L., Postlethwaite, R., Schild, G.C., and Allison, A.C. (1974). ANTIBODY 
RESPONSES TO ANTIGENIC DETERMINANTS OF INFLUENZA VIRUS 
HEMAGGLUTININ: I. Thymus Dependence of Antibody Formation and Thymus 
Independence of Immunological Memory. The Journal of Experimental Medicine 140, 
1559-1570. 
Von Stabsarzt, B., and Kutasati (1890). Ueber das zustandekommen der diphtherie-
immunität und der tetanus-immunität bei thieren. Deutsche Medizinische Wochenschrift 
16, 1113-1114. 
Vos, Q.L., Andrew; Wu, Zheng-Qi; Snapper, Clifford M.; Mond, James J. (2000). B-cell 
activation by T-cell-independent type 2 antigens as an integral part of the humoral 
immune response to pathogenic microorganisms. Immunological Reviews 176, 154-170. 
Wang, T.T., Tan, G.S., Hai, R., Pica, N., Petersen, E., Moran, T.M., and Palese, P. 
(2010). Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following 
Sequential Immunization with Different Hemagglutinins. PLoS Pathog 6, e1000796. 
Wang, Z., Raifu, M., Howard, M., Smith, L., Hansen, D., Goldsby, R., and Ratner, D. 
(2000). Universal PCR amplification of mouse immunoglobulin gene variable regions: 
the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ 
to 5′ exonuclease activity. Journal of Immunological Methods 233, 167-177. 
Warren, J., Mastroeni, P., Dougan, G., Noursadeghi, M., Cohen, J., Walport, M.J., and 
Botto, M. (2002). Increased Susceptibility of C1q-Deficient Mice to Salmonella enterica 
Serovar Typhimurium Infection. Infection and Immunity 70, 551-557. 
Webster, R.G. (1966). Original Antigenic Sin in Ferrets: the Response to Sequential 
Infections with Influenza Viruses. The Journal of Immunology 97, 177-183. 
	
	
123 
Webster, R.G., Kasel, J.A., Couch, R.B., and Laver, W.G. (1976). Influenza Virus 
Subunit Vaccines. II. Immunogenicity and Original Antigenic Sin in Humans. Journal of 
Infectious Diseases 134, 48-58. 
Wei, C.-J., Boyington, J.C., McTamney, P.M., Kong, W.-P., Pearce, M.B., Xu, L., 
Andersen, H., Rao, S., Tumpey, T.M., Yang, Z.-Y., et al. (2010). Induction of Broadly 
Neutralizing H1N1 Influenza Antibodies by Vaccination. Science 329, 1060-1064. 
Weisel, Florian J., Zuccarino-Catania, Griselda V., Chikina, M., and Shlomchik, Mark J. 
(2016). A Temporal Switch in the Germinal Center Determines Differential Output of 
Memory B and Plasma Cells. Immunity 44, 116-130. 
Wiley, D.C., Wilson, I.A., and Skehel, J.J. (1981). Structural identification of the 
antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in 
antigenic variation. Nature 289, 373-378. 
Wilson, I.A., Skehel, J.J., and Wiley, D.C. (1981). Structure of the haemagglutinin 
membrane glycoprotein of influenza virus at 3 [angst] resolution. Nature 289, 366-373. 
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., 
McCausland, M., Skountzou, I., Hornig, M., Lipkin, W.I., et al. (2011). Broadly cross-
reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 
influenza virus infection. The Journal of experimental medicine 208, 181-193. 
Xu, R., Ekiert, D.C., Krause, J.C., Hai, R., Crowe, J.E., and Wilson, I.A. (2010). 
Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. 
Science 328, 357-360. 
Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., 
Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. (2015). Hemagglutinin-stem 
nanoparticles generate heterosubtypic influenza protection. Nat Med 21, 1065-1070. 
Yu, X., Tsibane, T., McGraw, P.A., House, F.S., Keefer, C.J., Hicar, M.D., Tumpey, T.M., 
Pappas, C., Perrone, L.A., Martinez, O., et al. (2008). Neutralizing antibodies derived 
from the B cells of 1918 influenza pandemic survivors. Nature 455, 532-536. 
Zhang, Y., Meyer-Hermann, M., George, L.A., Figge, M.T., Khan, M., Goodall, M., 
Young, S.P., Reynolds, A., Falciani, F., Waisman, A., et al. (2013). Germinal center B 
cells govern their own fate via antibody feedback. The Journal of Experimental Medicine 
210, 457-464. 
	
	
124 
Zuccarino-Catania, G.V., Sadanand, S., Weisel, F.J., Tomayko, M.M., Meng, H.L., 
Kleinstein, S.H., Good-Jacobson, K.L., and Shlomchik, M.J. (2014). CD80 and PD-L2 
define functionally distinct memory B cell subsets that are independent of antibody 
isotype. Nature Immunology 15, 631-637. 
 
